View Future GrowthMannKind 과거 순이익 실적과거 기준 점검 0/6MannKind은 연평균 54.7%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 30.5%의 비율로 증가했습니다. 매출은 연평균 35.5%의 비율로 증가했습니다.핵심 정보54.71%순이익 성장률55.71%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률35.52%자기자본이익률n/a순이익률-6.63%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트공지 • Apr 30MannKind Corporation to Report Q1, 2026 Results on May 06, 2026MannKind Corporation announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 06, 2026공지 • Feb 18MannKind Corporation to Report Q4, 2025 Results on Feb 26, 2026MannKind Corporation announced that they will report Q4, 2025 results Pre-Market on Feb 26, 2026공지 • Oct 30MannKind Corporation to Report Q3, 2025 Results on Nov 05, 2025MannKind Corporation announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025공지 • Jul 31MannKind Corporation to Report Q2, 2025 Results on Aug 06, 2025MannKind Corporation announced that they will report Q2, 2025 results Pre-Market on Aug 06, 2025공지 • May 02MannKind Corporation to Report Q1, 2025 Results on May 08, 2025MannKind Corporation announced that they will report Q1, 2025 results Pre-Market on May 08, 2025공지 • Feb 20MannKind Corporation to Report Q4, 2024 Results on Feb 26, 2025MannKind Corporation announced that they will report Q4, 2024 results After-Market on Feb 26, 2025모든 업데이트 보기Recent updatesSeeking Alpha • May 07MannKind: It's ComplicatedSummary MannKind Corporation remains a Hold, as revenue growth is increasingly reliant on niche assets like Furoscix and faces margin pressure. United Therapeutics' launch of Tresmi threatens MNKD’s Tyvaso DPI royalties, intensifying competitive risks and highlighting MNKD’s junior partner status. Pipeline prospects, including MNKD-201 and ralinepag DPI, offer potential but face significant clinical, commercial, and competitive hurdles. Elevated SG&A and R&D costs signal a strategic pivot, but MNKD must prove its ability to thrive independently of UTHR. Read the full article on Seeking Alpha내러티브 업데이트 • May 04MNKD: Soft Mist Inhaler Risk Seen Resetting Future Royalty UpsideNarrative Update Analysts have trimmed their average price target on MannKind to about $8. This reflects updated assumptions for higher revenue growth but lower profit margins and a more moderate future P/E as they weigh potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans.공지 • Apr 30MannKind Corporation to Report Q1, 2026 Results on May 06, 2026MannKind Corporation announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 06, 2026내러티브 업데이트 • Apr 20MNKD: 2026 Pediatric Insulin Decision Will Reset Treprostinil Royalty RiskAnalysts have trimmed MannKind's average price target by about $0.33, reflecting slightly lower assumptions for fair value and profitability as they factor in potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans, even though some still see opportunity in the broader portfolio. Analyst Commentary Recent research has become more cautious on MannKind, with several firms trimming price targets and one moving to a more neutral rating as they reassess the risk and reward around Tyvaso DPI royalties and the impact of United Therapeutics' soft mist inhaler plans.공지 • Apr 09MannKind Corporation, Annual General Meeting, May 20, 2026MannKind Corporation, Annual General Meeting, May 20, 2026.내러티브 업데이트 • Apr 06MNKD: 2026 Pediatric Decision Will Define Royalty Overhang And Bullish SetupNarrative Update: MannKind MannKind's updated analyst price target has been reduced from about $7.50 to roughly $3.85, as analysts factor in softer modeled revenue growth, a higher discount rate, lower assumed future P/E and rising concerns that United Therapeutics' planned soft mist inhaler could weigh on the long term value of Tyvaso DPI royalties. Some still highlight potential support from Afrezza and Furoscix and argue the recent selloff may already reflect a worst case scenario.내러티브 업데이트 • Mar 22MNKD: 2026 Afrezza FDA Decisions Will Recast Treprostinil Royalty RiskAnalysts have trimmed their average price targets on MannKind by a few dollars into the mid single digit range, reflecting fresh concerns about long term Tyvaso DPI royalties as United Therapeutics pursues a soft mist inhaler, while still recognizing potential support from Furoscix and Afrezza. Analyst Commentary Recent Street commentary on MannKind highlights a split view, with many price targets pulled into a mid single digit to low double digit range as analysts weigh Tyvaso DPI royalty risk against potential contributions from Afrezza and Furoscix, as well as MannKind's broader pipeline.내러티브 업데이트 • Mar 08MNKD: 2026 FDA Decisions On Inhaled Insulin Will Reframe Royalty RiskAnalysts have trimmed their fair value view on MannKind to $7.50 from $9.61, citing lower price targets clustered around $3.50 to $11 as they factor in softer revenue growth and profit margin assumptions, as well as higher perceived risk tied to United Therapeutics' potential soft mist inhaler competition and the timing of Tyvaso DPI royalty data. Analyst Commentary Recent Street research on MannKind reflects a wide split in opinion, with some analysts focusing on potential upside from the broader product portfolio and others emphasizing new competitive risks to Tyvaso DPI royalties and collaboration revenue.내러티브 업데이트 • Feb 22MNKD: 2026 FDA Label And Pediatric Decisions Will Drive Bullish CaseAnalysts have kept their fair value estimate for MannKind steady while refining key inputs like discount rate, revenue growth, profit margin and future P/E. They link their current price targets, including one at $11, to what they see as multiple potential tailwinds tied to upcoming FDA decisions on Afrezza in 2026.공지 • Feb 18MannKind Corporation to Report Q4, 2025 Results on Feb 26, 2026MannKind Corporation announced that they will report Q4, 2025 results Pre-Market on Feb 26, 2026공지 • Feb 10Mannkind Corporation Announces First Patient Enrolled in Inhale-1St Pediatric Study Evaluating Afrezza®? for Youth with Newly-Diagnosed Type 1 Diabetes (T1d)MannKind Corporation announced that the first patient has been enrolled in INHALE-1ST, a clinical study evaluating the initiation of Afrezza (insulin human) Inhalation Powder shortly after a type 1 diabetes diagnosis in pediatric patients. INHALE-1ST is designed to assess the safety and efficacy of Afrezza used in combination with subcutaneously injected basal insulin once-daily in youth aged 10 to In October 2025, the FDA accepted for review a supplemental Biologics License Application (sBLA) for Afrezza Inhalation Powder in children and adolescents living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026. If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy. Afrezza (ins insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis or in patients that smoke or have recently stopped smoking. Acute bronchospasm has been observed in Afrezza-treated patients with asthma and chronic obstructive pulmonary disease (COPD); Afrezza is contraindicated in patients with chronic lung disease such as asthma or COPD; Before initiating Afrezza, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients. Most common adverse reactions are hypoglycemia, cough, and throat pain or irritation.내러티브 업데이트 • Feb 07MNKD: Upcoming FDA Decisions In 2026 Will Define Upside PotentialNarrative Update on MannKind Analysts have trimmed their price target on MannKind from $8.00 to $7.50, balancing reduced fair value and margin assumptions with expectations for stronger revenue growth. They also recognize that recent Street research still highlights potential tailwinds tied to upcoming FDA decisions and the updated pipeline outlook.공지 • Jan 26MannKind Corporation Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance When Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime TherapyMannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Prescribing Information for Afrezza®? (insulin human) Inhalation Powder, revising recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. The updated labeling was supported by modeling data and in vivo results from the Dose Optimization study and the INHALE-3 trial that demonstrated improved postprandial glucose outcomes following conversion to inhaled insulin using the now-approved conversion dose. The revised dosing recommendations, provided in the table below, include recommended dose conversions from injected mealtime insulin or insulin pump bolus dosing to the appropriate mealtime dosage of Afrezza and are intended to support a clinically appropriate and safe transition for adult patients initiating Afrezza. Please see the Full Prescribing Information for additional details. Afrezza (pronouncedUh-frezz-uh) Inhalation Powder is the only ultra rapid-acting inhaled insulin approved by the U.S. food and Drug Administration to improve glycemic control in adult patients with diabetes mellitus. Administration at the beginning of meals using a small, portable inhaler, Afrezza delivers insulin via MannKind's proprietary Technosphere®? technology, enabling ultra-rapid absorption through the lungs. Afrezza causes a decline in lung pulmonary function over time as measured by FEV1. In clinical trials excluding patients with chronic lung disease and lasting up to 2 years, Afrezza-treated patients experienced a small (40mL) but greater FEV1 decline than comparator-treated patients. Assess pulmonary function with spirometry at baseline, after the first 6 mon ths of therapy and annually thereafter even in the absence of pulmonary symptoms. If symptoms persist, discontinue Afrezza. In clinical trials, 2 cases of lung cancer were observed in patients exposed to Afrezza while no cases were reported for the comparators. In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk of lung cancer, consider whether the benefits of Afrezza use outweigh this potential risk. In clinical trials enrolling patients with type 1 diabetes, diabetic ketoacidosis (DKA) was more common in Afrezza-treated patients (0.43%; n=13) than in comparator-treated patients (0.14%; n=3). Patients with type 1 diabetes should always use Afrezza concomitantly with basal insulin. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with developing and commercializing product candidates and other risks detailed in MannKind's filings with the Securities and Exchange Commission ("SEC"), including under the "R Securities and Exchange Commission ("SEC").내러티브 업데이트 • Jan 23MNKD: 2026 FDA Label Decisions Will Clarify Underappreciated Upside PotentialNarrative Update on MannKind The analyst price target for MannKind has been reset to $10, reflecting updated views after one firm removed MNKD-101/NTM from its valuation while others highlight potential upside tied to upcoming FDA decisions and what they see as underappreciated tailwinds into 2026. Analyst Commentary Recent research on MannKind reflects a mix of optimism around upcoming FDA decisions and caution after the removal of MNKD-101/NTM from valuation models.내러티브 업데이트 • Jan 09MNKD: 2026 Regulatory Decisions Will Drive Reassessment Of Future ProspectsNarrative Update: MannKind Analyst Price Target Shift Analysts have reset their price targets on MannKind into a tighter US$10 to US$11 range, reflecting a mix of reduced expectations after the discontinuation of MNKD-101/NTM and continued optimism around potential 2026 tailwinds that are not yet fully reflected in the shares. Analyst Commentary Recent research views on MannKind reflect both optimism around potential 2026 catalysts and caution following pipeline changes and trial outcomes.공지 • Dec 24MannKind Corporation Shares FUROSCIX®? Business UpdatesMannKind Corporation announced two business updates--approval of the FUROSCIX®? (furosemide) On-body Infusor for pediatric patients and issuance of additional intellectual property protection for the investigational-stage FUROSCIX ReadyFlow™? Autoinjector, which is currently under review by the U.S. FDA. The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for FUROSCIX (furosemide) on-body Infusor, expanding the indication of this product to include pediatric patients weighing 43 kg or more. FUROSCIX was previously approved for the treatment of edema associated with chronic heart failure (CHF) and chronic kidney disease (CKD) in adults. This additional approval fulfills all post-marketing requirements outlined in the original approval letter under the Pediatric Research Equity Act. The U.S. Patent and Trademark Office (USPTO) issued five patents with claims that protect the FUROSCIX Ready flow Autoinjector. These patents cover the high-concentration liquid compositions of furosemide and associated methods of treatment potentially through 2040, further reinforcing MannKind's intellectual property position around this innovative drug-device combination. The patents would be listed in the FDA's Orange Book, if the FUROSCIX readyFlow Autoinjector is approved by the FDA. The newly issued patents complement previously issued patents supporting FUROSCIX and the FUROSCIXReadyFlow Autoinjector, creating a robust IP portfolio that is designed to protect the formulation and delivery approach for years to come.내러티브 업데이트 • Dec 23MNKD: Future Commercial Execution Will Offset Late Stage Pipeline DisappointmentAnalysts have trimmed their price target on MannKind to approximately $10 per share, a modest reduction that reflects the removal of MNKD-101/NTM from valuation assumptions, while improved revenue growth and profit margin forecasts partially offset the impact. Analyst Commentary Analyst reactions to the updated price target highlight a mixed outlook, with optimism around MannKind's core commercial performance tempered by concern over the setback in its development pipeline.내러티브 업데이트 • Dec 09MNKD: Future Commercial Portfolio Will Offset Pipeline Setback RiskAnalysts have reduced their price target on MannKind from $15.00 to $10.00 per share, citing the removal of MNKD-101/NTM from the pipeline following the discontinuation of the Phase 3 ICoN-1 trial after a futility assessment. Analyst Commentary Analysts view the updated price target as a recalibration of MannKind's valuation to reflect the loss of MNKD-101/NTM from the development pipeline, while still recognizing ongoing strengths in the core business and broader platform.공지 • Dec 02MannKind Corporation Announces U.S. FDA Accepts for Review its Supplemental New Drug Application of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Kidney DiseaseMannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA seeking approval for FUROSCIX ReadyFlow™? Autoinjector (SCP-111), developed to deliver a subcutaneous furosemide injection in under 10 seconds as an investigational alternative to the FDA-approved FUROSCIX®? (furosemide) On-body Infusor for treatment of edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD). The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2026. If approved, FUROSCIX Ready flow Autoinjector would provide a new option for patients with CHF or CKD to manage fluid buildup episodes from the convenience of their home rather than in a hospital setting. The FDA-approved FUROScIX On-body Infusor was approved for adult patients with edema in chronic heart failure in 2022 and in chronic kidney disease in 2025. The ReadyFlow Autoinjector would reduce administration time from five hours to under 10 seconds. The sNDA is supported by positive study results announced in August 2024. Furosemide via the ReadyFlow Autoinjector demonstrated a bioavailability of 107.3% (90% CI: 103.9 - 110.8), achieving the 90% confidence interval limit of 80 to 125%. Additionally, participants who utilized ReadyFlow Autoinjector had similar fluids, urinary sodium excretion and urinary potassium excretion at 6, 8, and 12 hours compared to IV furosemide, and was generally well tolerated with respect to injection site pain. Contact with water or other fluids and certain patient movements during treatment may cause the On-body Infusor to prematurely terminate infusion. Ensure patients can detect and respond to alarms. The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.내러티브 업데이트 • Nov 25MNKD: Recent Pipeline Setback Will Be Outweighed By Future Royalties ExpansionAnalysts have reduced their price target for MannKind from approximately $10.06 to $9.39, citing the discontinued Phase 3 ICoN-1 trial and adjusted pipeline expectations as the main factors for the revision. Analyst Commentary Analyst sentiment on MannKind has shifted in response to recent clinical trial results, pipeline updates, and royalty projections.내러티브 업데이트 • Nov 11MNKD: Acquisition Will Drive Revenue Diversification and Support Upside Re-RatingMannKind's fair value estimate has been revised down slightly to $10.06 per share from $10.57. Analysts are factoring in stronger revenue growth driven by TYVASO DPI royalties and the accretive acquisition of scPharmaceuticals, along with a modest change in profitability and updated discount rates.공지 • Nov 11MannKind Corporation Announces Discontinuing its Phase 3 Clinical Trial Evaluating Nebulized Inhalation Suspension of ClofazimineOn November 10, 2025, MannKind Corporation announced that it is discontinuing its Phase 3 clinical trial evaluating nebulized inhalation suspension of clofazimine (MNKD-101") for the treatment of refractory nontuberculous mycobacterial (NTM) lung disease (the ICoN-1 Study). The decision to discontinue the trial follows an analysis of sputum culture conversion data, conducted as part of routine study monitoring and in accordance with the trial protocol, for the first 46 participants who had completed the double-blind treatment phase of the study. None of these 46 participants showed evidence of sputum culture conversion, raising concerns regarding the likelihood of achieving the study's key primary endpoint. Following an ad hoc meeting of the data safety monitoring board ("DSMB") for the ICoN-1 Study on November 8, 2025, the DSMB reviewed the data and agreed with the decision to discontinue the trial due to futility. In this meeting and in all pastDSMB meetings, no safety issues were found. The Company intends to investigate the reasons for this outcome and use the findings to help guide the ongoing development of MNKD-102, the dry powder formulation of clofazimine, which is in the process of advancing from pre-clinical development towards Phase 1.공지 • Oct 30MannKind Corporation to Report Q3, 2025 Results on Nov 05, 2025MannKind Corporation announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025공지 • Oct 14Mannkind Corporation Announces U.S. Fda Accepts for Review Its Supplemental Biologics License Application for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with DiabetesMannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) seeking approval for Afrezza (insulin human) Inhalation Powder in children and adolescents living with type 1 or type 2 diabetes. The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2026. The sBLA is based on results from the Phase 3 INHALE-1 study in children and adolescents between the ages of 4-17 who are living with either type 1 or type2 diabetes. The 26-week open-label, randomized clinical trial evaluated Afrezza in combination with basal insulin vs. multiple daily injections (MDI) with basal insulin. Six-month topline results from INHALE-1 were reported in December 2024. The submission also included safety data from the study's 26-week extension phase in which all remaining MDI patients switched to Afrezza. Full results will be shared at the International Society for Pediatric and Adolescent Diabetes (ISPAD) in early November. Afrezza was first approved by the FDA for adults (age 18+) in June 2014 and is also approved in India and Brazil. It is recognized as part of the American Diabetes Association's Standards of Care. Afrezza (insulinhuman) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis or in patients that smoke or have recently stopped smoking.공지 • Oct 08MannKind Corporation (NasdaqGM:MNKD) completed the acquisition of scPharmaceuticals Inc. (NasdaqGS:SCPH).MannKind Corporation (NasdaqGM:MNKD) entered into a definitive Agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million on August 24, 2025. As part of agreement, MannKind Corporation will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals's common stock, at a price per share of (i) $5.35 in cash, without interest, subject to any applicable withholding taxes and (ii) one non-tradeable contingent value right (CVR), which represents the right to receive certain milestone payments of up to an aggregate of $1.00 in cash, payable upon achieving specific regulatory and net sales milestones. In case of termination of transaction, scPharmaceuticals will pay a termination fee of $9.48 million. Under the terms of the definitive merger agreement, MannKind will promptly commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals. MannKind and Blackstone amended their recently announced strategic financing agreement to provide $175 million of additional funding to support the acquisition. The transaction is subject to approval by regulatory board / committee, minimum tender and all applicable waiting periods under the HSR Act and the Required Antitrust Approvals shall have expired or been terminated and any approvals or clearances required thereunder shall have been obtained. The board of directors of the scPharmaceuticalst unanimously recommends that stockholders accept the Offer. The deal has been unanimously approved by the boards of MannKind Corporation and scPharmaceuticals. The transaction is expected to complete in fourth quarter of 2025. As on October 6, 2025, the tender offer expired and pursuant to the offer 73.47% shares where validly tendered. Jefferies LLC acted as financial advisor for MannKind Corporation. The team of Cooley LLP led by Barbara Borden, Rowook Park, Julia Kim, Mischi a Marca and Adam Longenbach acted as legal advisor for MannKind Corporation. Leerink Partners LLC acted as financial advisor for scPharmaceuticals Inc. The team of Latham & Watkins LLP led by Wesley Holmes, Scott Shean, Bret Stancil, Elisabeth Martin, Peter Handrinos, Alexandra McArthur, Josh Friedman, Katharine Moir, Betty Pang, Chad Jennings, Elizabeth Ohacted, Heather Deixler, Patrick English, Kristin Murphy and Steven Chinowsky as legal advisor for scPharmaceuticals Inc. MannKind Corporation (NasdaqGM:MNKD) completed the acquisition of scPharmaceuticals Inc. (NasdaqGS:SCPH) on October 7, 2025.공지 • Sep 30MannKind Corporation Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer, Effective September 29, 2025MannKind Corporation announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective September 29, 2025. Dr. Ahuja will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company’s executive leadership team. Dr. Ahuja brings to MannKind more than two decades of leadership experience across the biopharmaceutical industry, spanning development-stage companies and global pharmaceutical firms since 2003. Most recently, he served as the Development and Launch Leader for a late-stage DNA-based therapeutic at Kardigan Bio, a cardiology-focused biopharmaceutical company. Previously, Dr. Ahuja held senior leadership roles at Idorsia Pharmaceuticals, where he built out the US Medical department and launched multiple novel compounds. At Allergan, he served as Global Head of Medical Affairs, overseeing all therapeutic areas and a team of over 100 professionals across the U.S. and international markets. Earlier in his career, he was Global Medical Head for Takeda Pharmaceuticals’ cardiometabolic franchise, with a focus on diabetes and cardiovascular disease. Dr. Ahuja also held impactful roles at Pfizer, Novartis, and Tepha Inc. Dr. Ahuja earned his Doctor of Medicine from Washington University School of Medicine and completed his residency and fellowship training at Northwestern University and Harvard Medical School, respectively. As a board-certified physician, Dr. Ahuja practiced medicine on staff at Boston Children’s Hospital for over a decade. He also earned an MBA from Harvard Business School before embarking on his industry career.분석 기사 • Sep 03MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price JumpMannKind Corporation ( NASDAQ:MNKD ) shareholders would be excited to see that the share price has had a great month...내러티브 업데이트 • Aug 27Pipeline Advancements And International Expansion Will Shape Future MarketsAnalysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings. Analyst Commentary Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.공지 • Aug 25MannKind Corporation (NasdaqGM:MNKD) entered into a definitive agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million.MannKind Corporation (NasdaqGM:MNKD) entered into a definitive agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million on August 24, 2025. As part of agreement, MannKind Corporation will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals's common stock, at a price per share of (i) $5.35 in cash, without interest, subject to any applicable withholding taxes and (ii) one non-tradeable contingent value right (CVR), which represents the right to receive certain milestone payments of up to an aggregate of $1.00 in cash, payable upon achieving specific regulatory and net sales milestones. In case of termination of transaction, scPharmaceuticals will pay a termination fee of $9.48 million. Under the terms of the definitive merger agreement, MannKind will promptly commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals. MannKind and Blackstone amended their recently announced strategic financing agreement to provide $175 million of additional funding to support the acquisition. The transaction is subject to approval by regulatory board / committee, minimum tender and all applicable waiting periods under the HSR Act and the Required Antitrust Approvals shall have expired or been terminated and any approvals or clearances required thereunder shall have been obtained. The board of directors of the scPharmaceuticalst unanimously recommends that stockholders accept the Offer. The deal has been unanimously approved by the boards of MannKind Corporation and scPharmaceuticals. The transaction is expected to complete in fourth quarter of 2025. Jefferies LLC acted as financial advisor for MannKind Corporation. Barbara Borden and Rowook Park of Cooley LLP acted as legal advisor for MannKind Corporation. Leerink Partners LLC acted as financial advisor for scPharmaceuticals Inc. Scott Shean, Wesley Holmes and Bret Stancil of Latham & Watkins LLP acted as legal advisor for scPharmaceuticals Inc.공지 • Aug 07MannKind Corporation announced that it expects to receive $200 million in fundingMannKind Corp. announced a private placement of its senior secured term loans for gross proceeds of $200 million from new lender, Blackstone Alternative Credit Advisors LP on August 6, 2025. The company will raise $75 million in first tranche from initial term loan and $125 million in delayed draw term loan commitments, which the Company may draw at its option during the 24 months immediately following the closing date, subject to customary conditions set forth in the credit agreement. The Blackstone Credit Facility will mature on the fifth anniversary of the closing date. The loans thereunder bear interest at a rate per annum equal to 1, 3 or 6 month term SOFR, subject to a 2% floor, plus a margin of 4.75%. Interest is paid quarterly or, if the Company elects 1-month SOFR, monthly. The interest rate margin will increase to 5.00% at any time the Company’s ratio of indebtedness to adjusted EBITDA is greater than or equal to 5.00:1.00 as of the most recent fiscal quarter for which the Company has delivered financial statements. On the same date, the company has raised $75 in first tranche.공지 • Jul 31MannKind Corporation to Report Q2, 2025 Results on Aug 06, 2025MannKind Corporation announced that they will report Q2, 2025 results Pre-Market on Aug 06, 2025공지 • Jun 30+ 9 more updatesMannKind Corporation(NasdaqGM:MNKD) dropped from Russell 3000E IndexMannKind Corporation(NasdaqGM:MNKD) dropped from Russell 3000E Index공지 • Jun 10Mannkind Corporation to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) At American Diabetes Association's 85Th Scientific Sessions in Chicago, June 20-23MannKind Corporation will showcase inhaled insulin at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20-23 in Chicago. Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a "Future Ready" symposium. Dr. Haller is the Chair for MannKind's Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). The presentation/posters planned at ADA's 85th Scientific Sessions regarding the most recent advances in inhaled insulin treatment include: Symposium - Future Ready - Breakthrough in Pediatric Type 1 Diabetes Care Sunday, June 22 - 1:30 to 3:00 p.m. (Central) in Room W 181(A-C). Additionally, MannKind will host booth #1617 in the Exhibit Hall throughout the ADA's Scientific Sessions. Members of MannKind's Medical Education Team will be available for scientific exchange in the medical section of the booth. MannKind expects to issue the topline results from the full study pediatric data set with safety extension in second quarter of 2025 and anticipates submitting a Supplemental Biologics License Application in mid-2025 for a potential pediatric indication for Afrezza.분석 기사 • May 11Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their ForecastsShareholders might have noticed that MannKind Corporation ( NASDAQ:MNKD ) filed its first-quarter result this time last...공지 • May 02MannKind Corporation to Report Q1, 2025 Results on May 08, 2025MannKind Corporation announced that they will report Q1, 2025 results Pre-Market on May 08, 2025공지 • Apr 03MannKind Corporation, Annual General Meeting, May 14, 2025MannKind Corporation, Annual General Meeting, May 14, 2025.공지 • Mar 10MannKind Corporation Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza at the ATTD Conference, March 19-22MannKind Corporation will showcase data from recent studies of inhaled insulin across five presentations at the 18thInternational Conference on Advanced Technologies and Treatments for Diabetes to be held March 19-22 in Amsterdam. In addition to the planned presentations, MannKind will host booth #40 in the exhibit hall (Hall I) throughout ATTD. Members of MannKind's Clinical Education Team will be available for scientific exchange in the medical section of the booth. INHALE-1 is a Phase 3, randomized controlled trial in children and teenagers aged 4-17 with type 1 or type 2 diabetes to evaluate the efficacy and safety of inhaled insulin in combination with basal insulin versus multiple daily injections of rapid acting insulin in combination with basal insulin. The 26-week, open-label clinical trial randomized 230 pediatric subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA) in combination with basal insulin. the primary endpoint was a non-inferior change in HbA1c levels after 26 weeks. The 17-week results shared that the study met its primary efficacy endpoint of a non-inferior Change in HbA1c between baseline and week 17 compared to the usual care group. The 30-week results from the study expanded upon the positive 17-week data and showed that more people living with T1D were able to reach target A1c levels when they remain on Afrezza (plus basal insulin) or switch to Afrezza from usual care. The signature technologies - dry- powder formulations and inhalation devices - offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that issues that develop in the review by the FDA may subject to unanticipated delays or prevent from obtaining the expanded indication as well as other risks detailed in MannKind's filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of its Annual Report on Form 10-K for the year ended December 31, 2025.분석 기사 • Mar 01MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen NextMannKind Corporation ( NASDAQ:MNKD ) shareholders are probably feeling a little disappointed, since its shares fell...공지 • Feb 27MannKind Corporation has filed a Follow-on Equity Offering in the amount of $200 million.MannKind Corporation has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Common Stock Security Type: Common Stock공지 • Feb 20MannKind Corporation to Report Q4, 2024 Results on Feb 26, 2025MannKind Corporation announced that they will report Q4, 2024 results After-Market on Feb 26, 2025공지 • Jan 07+ 1 more updateMannkind Corporation Announces Resignation of Lauren Sabella as Executive Vice President, Operations, Effective July 18, 2025MannKind Corporation announced Lauren Sabella notified company of her intention to retire from the Company, effective July 18, 2025, and the board of directors of the Company appointed Ms. Sabella as Executive Vice President, Operations, effective January 6, 2025. Ms. Sabella will continue to be a member of the Company’s executive leadership team until her retirement date, overseeing the same operations of the Company as in her prior role except that she will no longer oversee the operations of the Company’s Endocrine Business Unit.Seeking Alpha • Dec 17MannKind Corporation: A Speculative Buy On IPF And Diabetes MarketsSummary MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, with significant market potential if successfully commercialized. The orphan lung pipeline includes MNKD-101 (Phase 3 for NTM lung disease) and MNKD-201 (Phase 1 for IPF), addressing high unmet needs. Despite high leverage, I believe MNKD's revenue growth prospects support a speculative "Buy" rating for investors seeking exposure to IPF and endocrine biotech niches. Read the full article on Seeking Alpha공지 • Dec 16MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)MannKind Corporation announced six-month results from its Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). MannKind expects to submit a request for a supplemental new drug application (sNDA) meeting with the U.S. Food and Drug Administration (FDA) in 1H 2025 to discuss the data and filing timeline. The INHALE-1 study is a 26-week, open-label clinical trial that randomized 230 subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA) in combination with basal insulin. The primary endpoint was a non-inferior change in HbA1c levels after 26 weeks. A 26-week extension phase in which all remaining MDI patients switched to Afrezza is still ongoing. Results were as follows: mITT analysis excludes one outlier from the primary ITT endpoint who failed to adhere to the study protocol. An analysis of the full intent-to-treat population (ITT) found that the between-group difference in mean HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (0.435%), largely driven by the variability of a single patient who did not adhere to the study protocol. A modified ITT (mITT) analysis, which excluded this subject, did not exceed the predetermined threshold of 0.4% (0.370%), thereby establishing the non-inferiority of Afrezza to MDI, which was the primary endpoint of the study. Over 26 weeks of treatment, no difference in lung function parameters were seen between the treatment groups. The Afrezza-treated patients had a mean FEV1 of 2.901 liters (99.6% of predicted) at baseline and 2.934 liters (96.6% of predicted) at 26 weeks. MDI-treated patients had corresponding mean FEV1 values of 2.948 liters (102.3% of predicted) and 2.957 liters (98% of predicted), respectively. Additional safety findings, including for hypoglycemia, did not show any significant concerns or differences between the treatment groups.공지 • Nov 05MannKind Corporation Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic DiseasesMannKind Corporation announced the successful completion of its first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The key highlights of the study included: Nintedanib DPI was shown to be safe and well tolerated in healthy volunteers with the tested doses and study duration; Participants did not experience typical adverse events seen with oral nintedanib; specifically, no GI or neurologic adverse events (AEs) were reported; Two types of AEs noted - cough and drop in FEV-1; These AEs were mild, transient, and fully recovered; These AEs were not dose-dependent and there was no pattern of recurrence or worsening with repeated dosing; No bronchospasm, wheezing, other symptoms, or change in vital signs were reported; No serious adverse events or study drug discontinuation. The completed Phase 1 was a single-site, randomized, placebo-controlled, single- (n=24) and multiple-ascending dose (n=16) study in healthy adult (older than 40 years old) participants. The primary objective of the study was to evaluate the safety and tolerability of nintedanib DPI. The secondary study objective was to evaluate the pharmacokinetics (PK) of MNKD-201. Additionally, the preclinical chronic toxicology study did not show any adverse findings and supports further development of nintedanib DPI.공지 • Nov 01MannKind Corporation to Report Q3, 2024 Results on Nov 07, 2024MannKind Corporation announced that they will report Q3, 2024 results After-Market on Nov 07, 2024Seeking Alpha • Oct 03MannKind Leverages Tyvaso DPI Strength In Pulmonary Market ExpansionSummary MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases. Financially, MannKind has strong liquidity but remains burdened by long-term debt obligations and modest net losses. I maintain a "buy" recommendation based on MannKind's solid revenue from Tyvaso DPI and its potential in expanding respiratory treatments. Read the full article on Seeking Alpha공지 • Oct 01Mannkind Corporation Announces Top-Level 30-Week Results from Its Phase 4 Inhale-3 StudyMannKind Corporation announced top-level 30-week results from its Phase 4 INHALE-3 study, in which additional patients living with type 1 diabetes achieved target A1c levels during the extension phase. The completer analysis which included all people on inhaled insulin, evaluated two separate groups - one that utilized Afrezza®? (plus basal insulin) over 30 weeks, and a second group of patients who switched to Afrezza at week 17 from usual care, defined as multiple daily injections (MDI), an automated insulin delivery system, (AID) or a pump without automation. There was continued improvement in the Afrezza (plus degludec)-treated group, with additional subjects achieving A1c 1) to identify potential lung disease in all patients. Most common adverse reactions are hypoglycemia, cough, and throat pain or irritation.공지 • Sep 19MannKind Corporation Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseMannKind Corporation announced that it has received clearance from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to initiate the Phase 3 study (ICoN-1) of Clofazimine Inhalation Suspension for the treatment of NTM lung disease. The global study is now cleared by health authorities to proceed in four countries (U.S., Japan, South Korea and Australia) with a fifth (Taiwan) expected in Fourth Quarter 2024. The ICoN-1 study was initiated in the United States in June 2024 and had its first patient randomized in September. In all, approximately 230 eligible participants will be enrolled and randomized at more than 100 sites across the U.S. and globally to ensure a minimum of 180 participants are evaluable for efficacy. Details of the ICoN-1 study and sites can be found at: ClinicalTrials.gov (NCT06418711).분석 기사 • Sep 18MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift TooDespite an already strong run, MannKind Corporation ( NASDAQ:MNKD ) shares have been powering on, with a gain of 28% in...새 내러티브 • Sep 12Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability Strong demand for Tyvaso DPI and advancements in pipeline drugs like clofazimine inhalation suspension highlight MannKind's successful commercial execution and promising revenue growth prospects. 공지 • Aug 14Mannkind Corporation Announces Board Changes, September 30, 2024MannKind Corporation announced that Kent Kresa has decided to retire from MannKind’s Board of Directors effective September 30, 2024. In addition, the Board of Directors has appointed Steven B. Binder to the Board, also effective September 30, 2024. Kresa, who has served on MannKind’s Board of Directors since June 2004, was Chairman from 2016 until December 2020. Upon his retirement from the MannKind Board, Mr. Kresa will continue to be associated with the company in the capacity of Chairman Emeritus. Binder previously served as MannKind’s Chief Financial Officer from July 2017 until April 2024 and currently serves as Executive Vice President, Special Projects. Mr. Binder will remain in that role until he joins the Board of Directors on September 30, 2024, after which he will no longer be an employee of the Company. With the addition of Binder, there will remain nine total members of the MannKind Board of Directors.공지 • Jul 31MannKind Corporation to Report Q2, 2024 Results on Aug 07, 2024MannKind Corporation announced that they will report Q2, 2024 results Pre-Market on Aug 07, 2024분석 기사 • Jul 17Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?Key Insights The projected fair value for MannKind is US$11.86 based on 2 Stage Free Cash Flow to Equity MannKind is...공지 • Jun 22MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 StudyMannKind Corporation announced positive 17-week results from the INHALE-3 study, a Phase 4 U.S. clinical trial evaluating Afrezza® (plus basal insulin) vs. usual care (defined as multiple daily injections (MDI), an automated insulin delivery system, (AID) or a pump without automation) utilizing a higher initial conversion dose from mealtime injectable insulin to inhaled insulin. The study, which was presented by the INHALE-3 investigational team at the American Diabetes Association’s (ADA) 84th Scientific Sessions in Orlando, met its primary efficacy endpoint of a non-inferior change in HbA1c between baseline and week 17 compared to the usual care group. Key sub-analysis findings included: More subjects utilizing inhaled insulin achieved glycemic targets: 30% of inhaled insulin group reached <7% (HbA1c) at 17 weeks vs. 17% of the usual care group; 21% of inhaled insulin group vs. 0% of usual care group met A1c goal of <7% if baseline was >7%; 24% of the Afrezza group and 13% of the usual care group achieved TIR above 70% with no increased hypoglycemia in the inhaled insulin group. No difference in CGM-measured hypoglycemia between the groups; Study helps to establish a titrated basal-bolus ratio that is approximately 70/30 inhaled insulin to basal vs. 50/50 for usual care; While more people met the glycemic target of A1c (less than 7%) with Afrezza, some subjects worsened when switching from usual care to inhaled insulin, potentially due to missing doses of inhaled insulin during the day and/or underdosing going into bedtime; More than 50% of subjects at the end of the study expressed an interest in continuing to use Afrezza. The INHALE-3 study is a 17-week, randomized controlled trial with a 13-week extension conducted across 19 U.S. sites. The study, which enrolled 141 patients (123 randomized), assigned participants over 18 years of age with T1D who are using MDI, an automated insulin delivery system, or a pump without automation to either continue their standard of care or initiate an insulin regimen of a daily basal injection plus Afrezza for boluses (mealtime and corrections). Both arms utilized continuous glucose monitoring to assess glucose control. A1c levels were obtained at baseline, 17 and 30-weeks. The full 30-week results of INHALE-3 will be presented at future conferences.Seeking Alpha • May 15MannKind Outperforms As Tyvaso DPI Captures Market ShareSummary MannKind's Q1 revenue rose 63% year-over-year; net income was $10.63 million, reversing a prior loss. Tyvaso DPI, utilizing MannKind’s technosphere technology, continues to capture significant PAH market interest. Despite high current assets, the Company's long-term liabilities exceed its assets, posing potential financial risks. Recommend buying MNKD for a barbell strategy portfolio, allocating a small portion to this high-alpha stock. Read the full article on Seeking AlphaNew Risk • May 09New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.5x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Negative equity (-US$230m). Minor Risk Shareholders have been diluted in the past year (3.0% increase in shares outstanding).공지 • May 08MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseMannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation of Clofazimine Inhalation Suspension (MNKD-101) for the treatment of nontuberculous mycobacterial (NTM) lung disease. Fast track designation is intended to facilitate the development, and expedite the review, of medicines to treat serious conditions and fill an unmet medical need. ICoN-1 is a multi-national, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of Clofazimine Inhalation Suspension when added to guideline-based therapy in adults with refractory NTM lung disease caused by Mycobacterium Avium Complex (MAC), followed by an open-label extension. This single registrational study anticipates getting underway in June 2024 in the U.S., and internationally in the second half of 2024. The U.S. FDA previously designated Clofazimine Inhalation Suspension as both an orphan drug and a qualified infectious disease product (QIDP) for the treatment of pulmonary NTM infections. A drug that receives orphan drug exclusivity receives seven years of exclusivity, and one that also earns QIDP designation, may receive an additional five years of market exclusivity.공지 • May 03MannKind Corporation to Report Q1, 2024 Results on May 08, 2024MannKind Corporation announced that they will report Q1, 2024 results on May 08, 2024공지 • Apr 30+ 1 more updateMannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesMannKind Corporation announced that it will proceed with a first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The Phase 1 randomized, double-blind, placebo-controlled, single- (SAD) and multiple-ascending dose (MAD) study will evaluate the safety, tolerability, and pharmacokinetics (PK) of nintedanib inhalation powder (MNKD-201) in healthy volunteers. The Pulmonary Fibrosis Foundation indicates that there are over 250,000 Americans living with pulmonary fibrosis (PF) and 50,000 new cases are diagnosed each year. While it is unknown the number of people affected by IPF - the most common form of pulmonary fibrosis - the latest estimates indicate that 1 in 200 adults over the age of 70 are impacted i n the United States. The company committed to using formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. The company signature technologies - dry- powder formulations and inhalation devices - offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating nationwide, the company are on a mission to give people control of their health and the freedom to live life.공지 • Apr 06MannKind Corporation, Annual General Meeting, May 15, 2024MannKind Corporation, Annual General Meeting, May 15, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect the nine nominees named herein as directors to serve for the upcoming year and until their successors are elected; to approve, on an advisory basis, the compensation of the named executive officers of company, as disclosed in company proxy statement for the Annual Meeting; and to discuss other matters.공지 • Mar 27+ 1 more updateMannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024MannKind Corporation announced that Steven B. Binder will retire from his position as Chief Financial Officer, effective April 22, 2024. Mr. Binder plans to remain at the company through the end of the year as Executive Vice President, Special Projects. Christopher Prentiss has been appointed as Chief Financial Officer, effective April 22, 2024. Mr. Prentiss will be a member of the company’s executive leadership team and will report to Michael Castagna, Chief Executive Officer. Chris has over 20 years of experience serving in financial leadership positions within the biopharma industry in both private and public companies. Since September 2022, Mr. Prentiss has served as Chief Financial Officer of ADARx Pharmaceuticals Inc., where he helped to raise nearly $250 million in funding. Between April 2015 and November 2021, he held a series of finance positions of increasing responsibility at the commercial-stage biotech company Adamas Pharmaceuticals Inc., culminating in Chief Financial Officer. His responsibilities at Adamas included finance, accounting, investor relations, information technology and facilities. During his tenure, the company launched GOCOVRI® (in 2018) as well as acquired OSMOLEX® ER. At the time Adamas was acquired by Supernus Pharmaceuticals Inc. His earlier career also included senior financial roles at InterMune Inc., Dynavax Technologies Corporation and MannKind. Mr. Prentiss began his career in the assurance practice at KPMG LLP. A licensed CPA (inactive) in California, he earned his Bachelor of Science degree in Accounting from Loyola Marymount University and an MBA from Indiana University’s Kelley School of Business.공지 • Mar 11MannKind Corporation Announces INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsMannKind Corporation announced initial meal challenge data from INHALE-3 that was presented by Dr. Irl B. Hirsch at the 17thInternational Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence on March 8th. INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care. The statistically significant findings included: Subjects utilizing inhaled insulin experienced significantly reduced post-meal hyperglycemia, compared with those who used subcutaneous rapid-acting analogues (RAA) delivered by MDI or pumps Area under the curve (AUC; 180 mg/dL) was reduced by 20%; Inhaled insulin subjects demonstrated significantly lower glucose excursions from baseline; Mean glucose excursions were reduced by 22%; In the inhaled insulin group, mean glucose levels peaked 15 minutes sooner than in the standard of care group despite inhaled insulin being given at start of the meal vs. RAA being administered 5-15 minutes prior to the meal. The 17-week endpoint results from INHALE-3 will be presented Saturday, June 22, during a symposium at the American Diabetes Association’s 84th Scientific Sessions in Orlando. INHALE-3 is a 17-week randomized controlled trial with a 13-week extension. The study, which enrolled 141 patients (123 randomized), assigned participants over 18 years of age with T1D who are using MDI, an automated insulin delivery system, or a pump without automation to either continue their standard of care or initiate an insulin regimen of a daily basal injection plus Afrezza for boluses (mealtime and corrections). Subjects utilizing inhaled insulin received a higher initial conversion dose than in the current label. Both arms utilized continuous glucose monitoring to assess glucose control. A1c levels were obtained at baseline, 17 and 30-weeks. For the meal challenge, the inhaled insulin group took an inhaled insulin dose immediately prior to a standardized meal (a 240 calorie nutritional shake) whereas those using usual care used RAA 5-15 minutes prior to the meal. Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis or in patients that smoke or have recently stopped smoking.분석 기사 • Mar 03This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This YearCelebrations may be in order for MannKind Corporation ( NASDAQ:MNKD ) shareholders, with the analysts delivering a...분석 기사 • Mar 02MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For ExcitementMannKind Corporation ( NASDAQ:MNKD ) shareholders would be excited to see that the share price has had a great month...Reported Earnings • Feb 29Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.045 loss per share (improved from US$0.34 loss in FY 2022). Revenue: US$199.0m (up 99% from FY 2022). Net loss: US$11.9m (loss narrowed 86% from FY 2022). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 23%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.공지 • Feb 21MannKind Corporation to Report Q4, 2023 Results on Feb 27, 2024MannKind Corporation announced that they will report Q4, 2023 results on Feb 27, 2024공지 • Feb 15MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®MannKind Corporation announced that it has fully enrolled 305 patients living with Type 1 or type 2 diabetes in its INHALE-1 study assessing efficacy and safety of inhaled insulin in the pediatric population. INHALE-1 is a 26-week open-label, randomized clinical trial with a 26-week extension. The primary endpoint is change in HbA1c level after 26 weeks. Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events. The multi-center study evaluated Afrezza in combination with basal insulin vs. multiple daily injections (MDI) of insulin in children and adolescents aged 4-17 who are living with type 1 or type 2 diabetes.Seeking Alpha • Feb 15MannKind's Tyvaso DPI Royalty Deal Signals UndervaluationSummary MannKind sold a 10% stake in Tyvaso DPI for $150 million upfront, with an additional $50 million possible, indicating the potential value of the remaining 9% to be upwards of $1.8 billion. Liquidia's likely entry into the market with a competing formulation poses a slight concern but is unlikely to significantly impact MannKind's market share. MannKind's Q3 earnings showed a strong year-over-year surge, but concerns over equity dilution and a debt-heavy balance sheet remain. MannKind's strategic moves, financial strengthening via the Sagard deal, and a manageable competitive landscape advocate for a "Buy" rating. Read the full article on Seeking Alpha분석 기사 • Jan 03MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is LackingMannKind Corporation's ( NASDAQ:MNKD ) price-to-sales (or "P/S") ratio of 6x might make it look like a strong buy right...Recent Insider Transactions Derivative • Dec 17CEO & Director notifies of intention to sell stockMichael Castagna intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of December. If the sale is conducted around the recent share price of US$4.00, it would amount to US$400k. For the year to December 2016, Michael's total compensation was 16% salary and 84% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Michael's direct individual holding has increased from 2.15m shares to 2.35m. There have been no trades via on-market transactions or options from company insiders in the last 12 months.Reported Earnings • Nov 09Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: EPS: US$0.006 (up from US$0.056 loss in 3Q 2022). Revenue: US$51.3m (up 56% from 3Q 2022). Net income: US$1.72m (up US$16.2m from 3Q 2022). Profit margin: 3.4% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 9% per year.공지 • Nov 07MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 DiabetesMannKind Corporation announced that it has fully enrolled patients in INHALE-3, a Phase 4 clinical trial evaluating inhaled insulin (combined with basal insulin) versus usual care in adults living with type 1 diabetes. INHALE-3 is a 17-week randomized controlled trial with a 13-week extension. The study will randomly assign participants over 18 years of age with T1D who are using Multiple Daily Injections (MDI), an automated insulin delivery (AID) system, or a pump without automation to either continue their usual care or adopt an insulin regimen of a daily basal injection plus Afrezza at mealtimes. Both arms will utilize continuous glucose monitoring to assess mealtime control and A1c levels.공지 • Nov 01MannKind Corporation to Report Q3, 2023 Results on Nov 07, 2023MannKind Corporation announced that they will report Q3, 2023 results on Nov 07, 2023Price Target Changed • Oct 10Price target increased by 9.8% to US$7.25Up from US$6.60, the current price target is an average from 6 analysts. New target price is 71% above last closing price of US$4.24. Stock is up 34% over the past year. The company is forecast to post a net loss per share of US$0.082 next year compared to a net loss per share of US$0.34 last year.Reported Earnings • Aug 08Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.02 loss per share (improved from US$0.11 loss in 2Q 2022). Revenue: US$48.6m (up 157% from 2Q 2022). Net loss: US$5.27m (loss narrowed 82% from 2Q 2022). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 53%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 50% per year, which means it is well ahead of earnings.공지 • Aug 01MannKind Corporation to Report Q2, 2023 Results on Aug 07, 2023MannKind Corporation announced that they will report Q2, 2023 results on Aug 07, 2023공지 • Jun 23Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes (T1d)MannKind Corporation announced that it is launching the INHALE-3 study to address the most important unmet need in adults living with T1D. INHALE-3 is a 17-week randomized controlled trial with a 13-week extension. The study will randomly assign participants over 18 years of age with T1D who are using MDI, an automated insulin delivery (AID) system, or a pump without automation to either continue their usual care or adopt an insulin regimen of basal injections plus Afrezza. Both arms will utilize continuous glucose monitoring to assess mealtime control and A1c levels. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly, and symptoms may differ across patients and change over time in the same patient. Patients and caregivers should be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. Decline in Pulmonary Function: AFREZZA causes a decline in lung pulmonary function over time as measured by FEV1. In clinical trials excluding patients with chronic lung disease and lasting up to 2 years, AFREZZA-treated patients experienced a small (40 mL) but greater FEV1 decline than comparator-treated patients. Assess pulmonary function with pulmonary function at baseline, after the first 6 months of therapy and annually thereafter even in the absence of pulmonary symptoms. In patients who have a decline of =20% in FEV1 from baseline, consider discontinuing AFREZZA. Consider more frequent lung function assessment in patients with pulmonary symptoms, e.g., wheezing, bronchospasm, breathing difficult, or persistent or recurring cough. If symptoms persist, discontinue AFREZZA. In clinical trials, 2 cases of lung cancer were observed in patients exposed to AFREZZA while no cases were reported for the comparators. In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. Two additional cases of lung cancer (squamous cell and lung blastoma) were reported in non-smokers exposed to AFREZZA after the trial completion. These data are insufficient to determine whether AFREZZA has an effect on lung or respiratory tract tumors. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk of lung cancer, consider whether the benefits of AFREZZA use outweigh this potential risk.Recent Insider Transactions Derivative • May 28CEO & Director notifies of intention to sell stockMichael Castagna intends to sell 150k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of May. If the sale is conducted around the recent share price of US$4.69, it would amount to US$703k. For the year to December 2016, Michael's total compensation was 16% salary and 84% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2022, Michael's direct individual holding has decreased from 2.05m shares to 1.98m. There has only been one transaction (US$18k sale) from insiders over the last 12 months.공지 • May 25Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical OfficerMannKind Corporation announced Burkhard Blank, MD, has joined the company as Executive Vice President, Research & Development and Chief Medical Officer, effective today. Blank will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company’s executive leadership team. Dr. Blank brings to MannKind more than 25 years of broad managerial experience and global drug development across all clinical, medical, and regulatory disciplines in multiple diseases areas. He has deep knowledge in the inhaled therapeutics space and has been instrumental in eight NDA and MAA submissions for small molecules, biologics, and drug-device combinations. Dr. Blank recently served as CMO/Head of R&D at Pharnext SA after serving seven years in the same position at Acorda Therapeutics. While at Acorda, he oversaw the Phase 3 development in North America and in Europe for Inbrija® (levodopa inhalation powder) for Parkinson’s disease with subsequent one-cycle approvals by the FDA and the EMA. Earlier in his career, Dr. Blank spent 20 years between Boehringer Ingelheim Pharmaceuticals in Ridgefield, CT, and Boehringer Ingelheim GmbH in Germany, serving in progressive leadership roles. Under his guidance, four products received approval including Spiriva® (for COPD) for which he oversaw development and led the presentation at the FDA advisory committee meeting. He has proven success in large and small organizations and will be based in Danbury. He received his medical degree from Universitaet Marburg, Germany, and is board-certified in internal medicine.분석 기사 • May 15Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share PriceWith a price-to-sales (or "P/S") ratio of 8.7x MannKind Corporation ( NASDAQ:MNKD ) may be sending bullish signals at...Reported Earnings • May 10First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.037 loss per share (improved from US$0.10 loss in 1Q 2022). Revenue: US$40.6m (up 239% from 1Q 2022). Net loss: US$9.80m (loss narrowed 62% from 1Q 2022). Revenue exceeded analyst estimates by 8.6%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 55% per year, which means it is well ahead of earnings.Major Estimate Revision • Mar 02Consensus EPS estimates fall by 17%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$167.0m to US$171.5m. Forecast EPS reduced from -US$0.12 to -US$0.14 per share. Biotechs industry in the US expected to see average net income decline 61% next year. Consensus price target up from US$6.17 to US$6.67. Share price fell 7.5% to US$4.83 over the past week.Price Target Changed • Feb 27Price target increased by 8.1% to US$6.67Up from US$6.17, the current price target is an average from 6 analysts. New target price is 24% above last closing price of US$5.38. Stock is up 105% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$0.34 last year.Reported Earnings • Feb 24Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$0.34 loss per share (further deteriorated from US$0.33 loss in FY 2021). Revenue: US$99.8m (up 32% from FY 2021). Net loss: US$87.4m (loss widened 8.0% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.7%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 62% per year, which means it is well ahead of earnings.공지 • Feb 17MannKind Corporation to Report Q4, 2022 Results on Feb 23, 2023MannKind Corporation announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 23, 2023분석 기사 • Jan 27MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share PriceKey Insights MannKind's estimated fair value is US$8.9 based on 2 Stage Free Cash Flow to Equity Current share price of...공지 • Jan 24MannKind Corporation Announces its Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung DiseaseMannKind Corporation announced clofazimine inhalation suspension (MNKD 101) will advance to an adaptive Phase 2/3 study. Additionally, a paper has been published in the American Society for Microbiology journal Antimicrobial Agents and Chemotherapy examining the potential for treatment of nontuberculous mycobacterial (NTM) infection through direct delivery of inhaled clofazimine to the lungs, overcoming the systemic toxicity witnessed in oral treatments. Pulmonary NTM infection is recognized as a major global health concern due to its rising prevalence worldwide. It is a serious infection that is caused by bacteria common in the environment that can lead to a reduction in lung function, cough, fatigue, and quality of life. It is estimated that approximately 86,000-180,000 people in the U.S. alone are living with NTM lung disease, and it is on the rise growing 8% each year with women, the elderly, and those with underlying lung conditions at greatest risk. MNKD-101 has been designated by the FDA as both an orphan lung and a qualified infectious disease product (QIDP) for the treatment of pulmonary NTM infections. The 28-day preclinical toxicology study included toxicokinetic analyses on days 29, 56, and 84. The findings indicated: Significant residual drug in lung tissue, and long lung residence post-dosing at all three dose levels. Drug concentrations in the lung remained well above the average NTM minimum inhibitory concentration (MIC, for MAC and Mabsc) at all time points, with measurable clofazimine levels at 28- and 56-days post-dosing. Study MKC-CI-001 was a Phase I randomized, double-blind, placebo-controlled, single- (SAD) and multiple-ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of MNKD-101. The dosing study evaluated low, mid, and high doses of clofazimine administered using a jet nebulizer. The key safety findings of the study included: Clofazimine inhalation solution found to be generally well tolerated at daily doses of up to 90 mg. No lab abnormalities, QT prolongation, or serious adverse events were identified.매출 및 비용 세부 내역MannKind가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqGM:MNKD 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 26361-241737331 Dec 2534961446630 Sep 25314291105030 Jun 25302331054931 Mar 2529830974731 Dec 2428628944630 Sep 2426722914430 Jun 2424812914131 Mar 242258933631 Dec 23199-12943130 Sep 23177-31962930 Jun 23158-47952331 Mar 23128-71952231 Dec 22100-87912030 Sep 2276-98921630 Jun 2266-88871631 Mar 2270-94811331 Dec 2175-81771230 Sep 2181-79721030 Jun 2175-8668831 Mar 2166-6162731 Dec 2065-5759630 Sep 2063-4558730 Jun 2062-4460731 Mar 2062-4663731 Dec 1963-5275730 Sep 1963-4777630 Jun 1953-6180631 Mar 1942-7185831 Dec 1828-8780930 Sep 1816-110851130 Jun 1813-119831331 Mar 1812-131801431 Dec 1711-117751430 Sep 1720-31671230 Jun 17180129621231 Mar 17178134551831 Dec 16175126471530 Sep 16162-205382030 Jun 160-364352131 Mar 160-363351931 Dec 150-368413030 Sep 150-1284439양질의 수익: MNKD 은(는) 현재 수익성이 없습니다.이익 마진 증가: MNKD는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: MNKD는 수익성이 없지만 지난 5년 동안 연평균 54.7%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 MNKD의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: MNKD은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: MNKD의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/07 06:18종가2026/05/07 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스MannKind Corporation는 29명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Thomas RussoBairdStephen V. ByrneBofA Global Researchnull nullBTIG26명의 분석가 더 보기
공지 • Apr 30MannKind Corporation to Report Q1, 2026 Results on May 06, 2026MannKind Corporation announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 06, 2026
공지 • Feb 18MannKind Corporation to Report Q4, 2025 Results on Feb 26, 2026MannKind Corporation announced that they will report Q4, 2025 results Pre-Market on Feb 26, 2026
공지 • Oct 30MannKind Corporation to Report Q3, 2025 Results on Nov 05, 2025MannKind Corporation announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025
공지 • Jul 31MannKind Corporation to Report Q2, 2025 Results on Aug 06, 2025MannKind Corporation announced that they will report Q2, 2025 results Pre-Market on Aug 06, 2025
공지 • May 02MannKind Corporation to Report Q1, 2025 Results on May 08, 2025MannKind Corporation announced that they will report Q1, 2025 results Pre-Market on May 08, 2025
공지 • Feb 20MannKind Corporation to Report Q4, 2024 Results on Feb 26, 2025MannKind Corporation announced that they will report Q4, 2024 results After-Market on Feb 26, 2025
Seeking Alpha • May 07MannKind: It's ComplicatedSummary MannKind Corporation remains a Hold, as revenue growth is increasingly reliant on niche assets like Furoscix and faces margin pressure. United Therapeutics' launch of Tresmi threatens MNKD’s Tyvaso DPI royalties, intensifying competitive risks and highlighting MNKD’s junior partner status. Pipeline prospects, including MNKD-201 and ralinepag DPI, offer potential but face significant clinical, commercial, and competitive hurdles. Elevated SG&A and R&D costs signal a strategic pivot, but MNKD must prove its ability to thrive independently of UTHR. Read the full article on Seeking Alpha
내러티브 업데이트 • May 04MNKD: Soft Mist Inhaler Risk Seen Resetting Future Royalty UpsideNarrative Update Analysts have trimmed their average price target on MannKind to about $8. This reflects updated assumptions for higher revenue growth but lower profit margins and a more moderate future P/E as they weigh potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans.
공지 • Apr 30MannKind Corporation to Report Q1, 2026 Results on May 06, 2026MannKind Corporation announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 06, 2026
내러티브 업데이트 • Apr 20MNKD: 2026 Pediatric Insulin Decision Will Reset Treprostinil Royalty RiskAnalysts have trimmed MannKind's average price target by about $0.33, reflecting slightly lower assumptions for fair value and profitability as they factor in potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans, even though some still see opportunity in the broader portfolio. Analyst Commentary Recent research has become more cautious on MannKind, with several firms trimming price targets and one moving to a more neutral rating as they reassess the risk and reward around Tyvaso DPI royalties and the impact of United Therapeutics' soft mist inhaler plans.
공지 • Apr 09MannKind Corporation, Annual General Meeting, May 20, 2026MannKind Corporation, Annual General Meeting, May 20, 2026.
내러티브 업데이트 • Apr 06MNKD: 2026 Pediatric Decision Will Define Royalty Overhang And Bullish SetupNarrative Update: MannKind MannKind's updated analyst price target has been reduced from about $7.50 to roughly $3.85, as analysts factor in softer modeled revenue growth, a higher discount rate, lower assumed future P/E and rising concerns that United Therapeutics' planned soft mist inhaler could weigh on the long term value of Tyvaso DPI royalties. Some still highlight potential support from Afrezza and Furoscix and argue the recent selloff may already reflect a worst case scenario.
내러티브 업데이트 • Mar 22MNKD: 2026 Afrezza FDA Decisions Will Recast Treprostinil Royalty RiskAnalysts have trimmed their average price targets on MannKind by a few dollars into the mid single digit range, reflecting fresh concerns about long term Tyvaso DPI royalties as United Therapeutics pursues a soft mist inhaler, while still recognizing potential support from Furoscix and Afrezza. Analyst Commentary Recent Street commentary on MannKind highlights a split view, with many price targets pulled into a mid single digit to low double digit range as analysts weigh Tyvaso DPI royalty risk against potential contributions from Afrezza and Furoscix, as well as MannKind's broader pipeline.
내러티브 업데이트 • Mar 08MNKD: 2026 FDA Decisions On Inhaled Insulin Will Reframe Royalty RiskAnalysts have trimmed their fair value view on MannKind to $7.50 from $9.61, citing lower price targets clustered around $3.50 to $11 as they factor in softer revenue growth and profit margin assumptions, as well as higher perceived risk tied to United Therapeutics' potential soft mist inhaler competition and the timing of Tyvaso DPI royalty data. Analyst Commentary Recent Street research on MannKind reflects a wide split in opinion, with some analysts focusing on potential upside from the broader product portfolio and others emphasizing new competitive risks to Tyvaso DPI royalties and collaboration revenue.
내러티브 업데이트 • Feb 22MNKD: 2026 FDA Label And Pediatric Decisions Will Drive Bullish CaseAnalysts have kept their fair value estimate for MannKind steady while refining key inputs like discount rate, revenue growth, profit margin and future P/E. They link their current price targets, including one at $11, to what they see as multiple potential tailwinds tied to upcoming FDA decisions on Afrezza in 2026.
공지 • Feb 18MannKind Corporation to Report Q4, 2025 Results on Feb 26, 2026MannKind Corporation announced that they will report Q4, 2025 results Pre-Market on Feb 26, 2026
공지 • Feb 10Mannkind Corporation Announces First Patient Enrolled in Inhale-1St Pediatric Study Evaluating Afrezza®? for Youth with Newly-Diagnosed Type 1 Diabetes (T1d)MannKind Corporation announced that the first patient has been enrolled in INHALE-1ST, a clinical study evaluating the initiation of Afrezza (insulin human) Inhalation Powder shortly after a type 1 diabetes diagnosis in pediatric patients. INHALE-1ST is designed to assess the safety and efficacy of Afrezza used in combination with subcutaneously injected basal insulin once-daily in youth aged 10 to In October 2025, the FDA accepted for review a supplemental Biologics License Application (sBLA) for Afrezza Inhalation Powder in children and adolescents living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026. If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy. Afrezza (ins insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis or in patients that smoke or have recently stopped smoking. Acute bronchospasm has been observed in Afrezza-treated patients with asthma and chronic obstructive pulmonary disease (COPD); Afrezza is contraindicated in patients with chronic lung disease such as asthma or COPD; Before initiating Afrezza, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients. Most common adverse reactions are hypoglycemia, cough, and throat pain or irritation.
내러티브 업데이트 • Feb 07MNKD: Upcoming FDA Decisions In 2026 Will Define Upside PotentialNarrative Update on MannKind Analysts have trimmed their price target on MannKind from $8.00 to $7.50, balancing reduced fair value and margin assumptions with expectations for stronger revenue growth. They also recognize that recent Street research still highlights potential tailwinds tied to upcoming FDA decisions and the updated pipeline outlook.
공지 • Jan 26MannKind Corporation Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance When Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime TherapyMannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Prescribing Information for Afrezza®? (insulin human) Inhalation Powder, revising recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. The updated labeling was supported by modeling data and in vivo results from the Dose Optimization study and the INHALE-3 trial that demonstrated improved postprandial glucose outcomes following conversion to inhaled insulin using the now-approved conversion dose. The revised dosing recommendations, provided in the table below, include recommended dose conversions from injected mealtime insulin or insulin pump bolus dosing to the appropriate mealtime dosage of Afrezza and are intended to support a clinically appropriate and safe transition for adult patients initiating Afrezza. Please see the Full Prescribing Information for additional details. Afrezza (pronouncedUh-frezz-uh) Inhalation Powder is the only ultra rapid-acting inhaled insulin approved by the U.S. food and Drug Administration to improve glycemic control in adult patients with diabetes mellitus. Administration at the beginning of meals using a small, portable inhaler, Afrezza delivers insulin via MannKind's proprietary Technosphere®? technology, enabling ultra-rapid absorption through the lungs. Afrezza causes a decline in lung pulmonary function over time as measured by FEV1. In clinical trials excluding patients with chronic lung disease and lasting up to 2 years, Afrezza-treated patients experienced a small (40mL) but greater FEV1 decline than comparator-treated patients. Assess pulmonary function with spirometry at baseline, after the first 6 mon ths of therapy and annually thereafter even in the absence of pulmonary symptoms. If symptoms persist, discontinue Afrezza. In clinical trials, 2 cases of lung cancer were observed in patients exposed to Afrezza while no cases were reported for the comparators. In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk of lung cancer, consider whether the benefits of Afrezza use outweigh this potential risk. In clinical trials enrolling patients with type 1 diabetes, diabetic ketoacidosis (DKA) was more common in Afrezza-treated patients (0.43%; n=13) than in comparator-treated patients (0.14%; n=3). Patients with type 1 diabetes should always use Afrezza concomitantly with basal insulin. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with developing and commercializing product candidates and other risks detailed in MannKind's filings with the Securities and Exchange Commission ("SEC"), including under the "R Securities and Exchange Commission ("SEC").
내러티브 업데이트 • Jan 23MNKD: 2026 FDA Label Decisions Will Clarify Underappreciated Upside PotentialNarrative Update on MannKind The analyst price target for MannKind has been reset to $10, reflecting updated views after one firm removed MNKD-101/NTM from its valuation while others highlight potential upside tied to upcoming FDA decisions and what they see as underappreciated tailwinds into 2026. Analyst Commentary Recent research on MannKind reflects a mix of optimism around upcoming FDA decisions and caution after the removal of MNKD-101/NTM from valuation models.
내러티브 업데이트 • Jan 09MNKD: 2026 Regulatory Decisions Will Drive Reassessment Of Future ProspectsNarrative Update: MannKind Analyst Price Target Shift Analysts have reset their price targets on MannKind into a tighter US$10 to US$11 range, reflecting a mix of reduced expectations after the discontinuation of MNKD-101/NTM and continued optimism around potential 2026 tailwinds that are not yet fully reflected in the shares. Analyst Commentary Recent research views on MannKind reflect both optimism around potential 2026 catalysts and caution following pipeline changes and trial outcomes.
공지 • Dec 24MannKind Corporation Shares FUROSCIX®? Business UpdatesMannKind Corporation announced two business updates--approval of the FUROSCIX®? (furosemide) On-body Infusor for pediatric patients and issuance of additional intellectual property protection for the investigational-stage FUROSCIX ReadyFlow™? Autoinjector, which is currently under review by the U.S. FDA. The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for FUROSCIX (furosemide) on-body Infusor, expanding the indication of this product to include pediatric patients weighing 43 kg or more. FUROSCIX was previously approved for the treatment of edema associated with chronic heart failure (CHF) and chronic kidney disease (CKD) in adults. This additional approval fulfills all post-marketing requirements outlined in the original approval letter under the Pediatric Research Equity Act. The U.S. Patent and Trademark Office (USPTO) issued five patents with claims that protect the FUROSCIX Ready flow Autoinjector. These patents cover the high-concentration liquid compositions of furosemide and associated methods of treatment potentially through 2040, further reinforcing MannKind's intellectual property position around this innovative drug-device combination. The patents would be listed in the FDA's Orange Book, if the FUROSCIX readyFlow Autoinjector is approved by the FDA. The newly issued patents complement previously issued patents supporting FUROSCIX and the FUROSCIXReadyFlow Autoinjector, creating a robust IP portfolio that is designed to protect the formulation and delivery approach for years to come.
내러티브 업데이트 • Dec 23MNKD: Future Commercial Execution Will Offset Late Stage Pipeline DisappointmentAnalysts have trimmed their price target on MannKind to approximately $10 per share, a modest reduction that reflects the removal of MNKD-101/NTM from valuation assumptions, while improved revenue growth and profit margin forecasts partially offset the impact. Analyst Commentary Analyst reactions to the updated price target highlight a mixed outlook, with optimism around MannKind's core commercial performance tempered by concern over the setback in its development pipeline.
내러티브 업데이트 • Dec 09MNKD: Future Commercial Portfolio Will Offset Pipeline Setback RiskAnalysts have reduced their price target on MannKind from $15.00 to $10.00 per share, citing the removal of MNKD-101/NTM from the pipeline following the discontinuation of the Phase 3 ICoN-1 trial after a futility assessment. Analyst Commentary Analysts view the updated price target as a recalibration of MannKind's valuation to reflect the loss of MNKD-101/NTM from the development pipeline, while still recognizing ongoing strengths in the core business and broader platform.
공지 • Dec 02MannKind Corporation Announces U.S. FDA Accepts for Review its Supplemental New Drug Application of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Kidney DiseaseMannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA seeking approval for FUROSCIX ReadyFlow™? Autoinjector (SCP-111), developed to deliver a subcutaneous furosemide injection in under 10 seconds as an investigational alternative to the FDA-approved FUROSCIX®? (furosemide) On-body Infusor for treatment of edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD). The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2026. If approved, FUROSCIX Ready flow Autoinjector would provide a new option for patients with CHF or CKD to manage fluid buildup episodes from the convenience of their home rather than in a hospital setting. The FDA-approved FUROScIX On-body Infusor was approved for adult patients with edema in chronic heart failure in 2022 and in chronic kidney disease in 2025. The ReadyFlow Autoinjector would reduce administration time from five hours to under 10 seconds. The sNDA is supported by positive study results announced in August 2024. Furosemide via the ReadyFlow Autoinjector demonstrated a bioavailability of 107.3% (90% CI: 103.9 - 110.8), achieving the 90% confidence interval limit of 80 to 125%. Additionally, participants who utilized ReadyFlow Autoinjector had similar fluids, urinary sodium excretion and urinary potassium excretion at 6, 8, and 12 hours compared to IV furosemide, and was generally well tolerated with respect to injection site pain. Contact with water or other fluids and certain patient movements during treatment may cause the On-body Infusor to prematurely terminate infusion. Ensure patients can detect and respond to alarms. The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.
내러티브 업데이트 • Nov 25MNKD: Recent Pipeline Setback Will Be Outweighed By Future Royalties ExpansionAnalysts have reduced their price target for MannKind from approximately $10.06 to $9.39, citing the discontinued Phase 3 ICoN-1 trial and adjusted pipeline expectations as the main factors for the revision. Analyst Commentary Analyst sentiment on MannKind has shifted in response to recent clinical trial results, pipeline updates, and royalty projections.
내러티브 업데이트 • Nov 11MNKD: Acquisition Will Drive Revenue Diversification and Support Upside Re-RatingMannKind's fair value estimate has been revised down slightly to $10.06 per share from $10.57. Analysts are factoring in stronger revenue growth driven by TYVASO DPI royalties and the accretive acquisition of scPharmaceuticals, along with a modest change in profitability and updated discount rates.
공지 • Nov 11MannKind Corporation Announces Discontinuing its Phase 3 Clinical Trial Evaluating Nebulized Inhalation Suspension of ClofazimineOn November 10, 2025, MannKind Corporation announced that it is discontinuing its Phase 3 clinical trial evaluating nebulized inhalation suspension of clofazimine (MNKD-101") for the treatment of refractory nontuberculous mycobacterial (NTM) lung disease (the ICoN-1 Study). The decision to discontinue the trial follows an analysis of sputum culture conversion data, conducted as part of routine study monitoring and in accordance with the trial protocol, for the first 46 participants who had completed the double-blind treatment phase of the study. None of these 46 participants showed evidence of sputum culture conversion, raising concerns regarding the likelihood of achieving the study's key primary endpoint. Following an ad hoc meeting of the data safety monitoring board ("DSMB") for the ICoN-1 Study on November 8, 2025, the DSMB reviewed the data and agreed with the decision to discontinue the trial due to futility. In this meeting and in all pastDSMB meetings, no safety issues were found. The Company intends to investigate the reasons for this outcome and use the findings to help guide the ongoing development of MNKD-102, the dry powder formulation of clofazimine, which is in the process of advancing from pre-clinical development towards Phase 1.
공지 • Oct 30MannKind Corporation to Report Q3, 2025 Results on Nov 05, 2025MannKind Corporation announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025
공지 • Oct 14Mannkind Corporation Announces U.S. Fda Accepts for Review Its Supplemental Biologics License Application for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with DiabetesMannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) seeking approval for Afrezza (insulin human) Inhalation Powder in children and adolescents living with type 1 or type 2 diabetes. The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2026. The sBLA is based on results from the Phase 3 INHALE-1 study in children and adolescents between the ages of 4-17 who are living with either type 1 or type2 diabetes. The 26-week open-label, randomized clinical trial evaluated Afrezza in combination with basal insulin vs. multiple daily injections (MDI) with basal insulin. Six-month topline results from INHALE-1 were reported in December 2024. The submission also included safety data from the study's 26-week extension phase in which all remaining MDI patients switched to Afrezza. Full results will be shared at the International Society for Pediatric and Adolescent Diabetes (ISPAD) in early November. Afrezza was first approved by the FDA for adults (age 18+) in June 2014 and is also approved in India and Brazil. It is recognized as part of the American Diabetes Association's Standards of Care. Afrezza (insulinhuman) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis or in patients that smoke or have recently stopped smoking.
공지 • Oct 08MannKind Corporation (NasdaqGM:MNKD) completed the acquisition of scPharmaceuticals Inc. (NasdaqGS:SCPH).MannKind Corporation (NasdaqGM:MNKD) entered into a definitive Agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million on August 24, 2025. As part of agreement, MannKind Corporation will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals's common stock, at a price per share of (i) $5.35 in cash, without interest, subject to any applicable withholding taxes and (ii) one non-tradeable contingent value right (CVR), which represents the right to receive certain milestone payments of up to an aggregate of $1.00 in cash, payable upon achieving specific regulatory and net sales milestones. In case of termination of transaction, scPharmaceuticals will pay a termination fee of $9.48 million. Under the terms of the definitive merger agreement, MannKind will promptly commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals. MannKind and Blackstone amended their recently announced strategic financing agreement to provide $175 million of additional funding to support the acquisition. The transaction is subject to approval by regulatory board / committee, minimum tender and all applicable waiting periods under the HSR Act and the Required Antitrust Approvals shall have expired or been terminated and any approvals or clearances required thereunder shall have been obtained. The board of directors of the scPharmaceuticalst unanimously recommends that stockholders accept the Offer. The deal has been unanimously approved by the boards of MannKind Corporation and scPharmaceuticals. The transaction is expected to complete in fourth quarter of 2025. As on October 6, 2025, the tender offer expired and pursuant to the offer 73.47% shares where validly tendered. Jefferies LLC acted as financial advisor for MannKind Corporation. The team of Cooley LLP led by Barbara Borden, Rowook Park, Julia Kim, Mischi a Marca and Adam Longenbach acted as legal advisor for MannKind Corporation. Leerink Partners LLC acted as financial advisor for scPharmaceuticals Inc. The team of Latham & Watkins LLP led by Wesley Holmes, Scott Shean, Bret Stancil, Elisabeth Martin, Peter Handrinos, Alexandra McArthur, Josh Friedman, Katharine Moir, Betty Pang, Chad Jennings, Elizabeth Ohacted, Heather Deixler, Patrick English, Kristin Murphy and Steven Chinowsky as legal advisor for scPharmaceuticals Inc. MannKind Corporation (NasdaqGM:MNKD) completed the acquisition of scPharmaceuticals Inc. (NasdaqGS:SCPH) on October 7, 2025.
공지 • Sep 30MannKind Corporation Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer, Effective September 29, 2025MannKind Corporation announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective September 29, 2025. Dr. Ahuja will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company’s executive leadership team. Dr. Ahuja brings to MannKind more than two decades of leadership experience across the biopharmaceutical industry, spanning development-stage companies and global pharmaceutical firms since 2003. Most recently, he served as the Development and Launch Leader for a late-stage DNA-based therapeutic at Kardigan Bio, a cardiology-focused biopharmaceutical company. Previously, Dr. Ahuja held senior leadership roles at Idorsia Pharmaceuticals, where he built out the US Medical department and launched multiple novel compounds. At Allergan, he served as Global Head of Medical Affairs, overseeing all therapeutic areas and a team of over 100 professionals across the U.S. and international markets. Earlier in his career, he was Global Medical Head for Takeda Pharmaceuticals’ cardiometabolic franchise, with a focus on diabetes and cardiovascular disease. Dr. Ahuja also held impactful roles at Pfizer, Novartis, and Tepha Inc. Dr. Ahuja earned his Doctor of Medicine from Washington University School of Medicine and completed his residency and fellowship training at Northwestern University and Harvard Medical School, respectively. As a board-certified physician, Dr. Ahuja practiced medicine on staff at Boston Children’s Hospital for over a decade. He also earned an MBA from Harvard Business School before embarking on his industry career.
분석 기사 • Sep 03MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price JumpMannKind Corporation ( NASDAQ:MNKD ) shareholders would be excited to see that the share price has had a great month...
내러티브 업데이트 • Aug 27Pipeline Advancements And International Expansion Will Shape Future MarketsAnalysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings. Analyst Commentary Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.
공지 • Aug 25MannKind Corporation (NasdaqGM:MNKD) entered into a definitive agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million.MannKind Corporation (NasdaqGM:MNKD) entered into a definitive agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million on August 24, 2025. As part of agreement, MannKind Corporation will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals's common stock, at a price per share of (i) $5.35 in cash, without interest, subject to any applicable withholding taxes and (ii) one non-tradeable contingent value right (CVR), which represents the right to receive certain milestone payments of up to an aggregate of $1.00 in cash, payable upon achieving specific regulatory and net sales milestones. In case of termination of transaction, scPharmaceuticals will pay a termination fee of $9.48 million. Under the terms of the definitive merger agreement, MannKind will promptly commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals. MannKind and Blackstone amended their recently announced strategic financing agreement to provide $175 million of additional funding to support the acquisition. The transaction is subject to approval by regulatory board / committee, minimum tender and all applicable waiting periods under the HSR Act and the Required Antitrust Approvals shall have expired or been terminated and any approvals or clearances required thereunder shall have been obtained. The board of directors of the scPharmaceuticalst unanimously recommends that stockholders accept the Offer. The deal has been unanimously approved by the boards of MannKind Corporation and scPharmaceuticals. The transaction is expected to complete in fourth quarter of 2025. Jefferies LLC acted as financial advisor for MannKind Corporation. Barbara Borden and Rowook Park of Cooley LLP acted as legal advisor for MannKind Corporation. Leerink Partners LLC acted as financial advisor for scPharmaceuticals Inc. Scott Shean, Wesley Holmes and Bret Stancil of Latham & Watkins LLP acted as legal advisor for scPharmaceuticals Inc.
공지 • Aug 07MannKind Corporation announced that it expects to receive $200 million in fundingMannKind Corp. announced a private placement of its senior secured term loans for gross proceeds of $200 million from new lender, Blackstone Alternative Credit Advisors LP on August 6, 2025. The company will raise $75 million in first tranche from initial term loan and $125 million in delayed draw term loan commitments, which the Company may draw at its option during the 24 months immediately following the closing date, subject to customary conditions set forth in the credit agreement. The Blackstone Credit Facility will mature on the fifth anniversary of the closing date. The loans thereunder bear interest at a rate per annum equal to 1, 3 or 6 month term SOFR, subject to a 2% floor, plus a margin of 4.75%. Interest is paid quarterly or, if the Company elects 1-month SOFR, monthly. The interest rate margin will increase to 5.00% at any time the Company’s ratio of indebtedness to adjusted EBITDA is greater than or equal to 5.00:1.00 as of the most recent fiscal quarter for which the Company has delivered financial statements. On the same date, the company has raised $75 in first tranche.
공지 • Jul 31MannKind Corporation to Report Q2, 2025 Results on Aug 06, 2025MannKind Corporation announced that they will report Q2, 2025 results Pre-Market on Aug 06, 2025
공지 • Jun 30+ 9 more updatesMannKind Corporation(NasdaqGM:MNKD) dropped from Russell 3000E IndexMannKind Corporation(NasdaqGM:MNKD) dropped from Russell 3000E Index
공지 • Jun 10Mannkind Corporation to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) At American Diabetes Association's 85Th Scientific Sessions in Chicago, June 20-23MannKind Corporation will showcase inhaled insulin at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20-23 in Chicago. Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a "Future Ready" symposium. Dr. Haller is the Chair for MannKind's Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). The presentation/posters planned at ADA's 85th Scientific Sessions regarding the most recent advances in inhaled insulin treatment include: Symposium - Future Ready - Breakthrough in Pediatric Type 1 Diabetes Care Sunday, June 22 - 1:30 to 3:00 p.m. (Central) in Room W 181(A-C). Additionally, MannKind will host booth #1617 in the Exhibit Hall throughout the ADA's Scientific Sessions. Members of MannKind's Medical Education Team will be available for scientific exchange in the medical section of the booth. MannKind expects to issue the topline results from the full study pediatric data set with safety extension in second quarter of 2025 and anticipates submitting a Supplemental Biologics License Application in mid-2025 for a potential pediatric indication for Afrezza.
분석 기사 • May 11Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their ForecastsShareholders might have noticed that MannKind Corporation ( NASDAQ:MNKD ) filed its first-quarter result this time last...
공지 • May 02MannKind Corporation to Report Q1, 2025 Results on May 08, 2025MannKind Corporation announced that they will report Q1, 2025 results Pre-Market on May 08, 2025
공지 • Apr 03MannKind Corporation, Annual General Meeting, May 14, 2025MannKind Corporation, Annual General Meeting, May 14, 2025.
공지 • Mar 10MannKind Corporation Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza at the ATTD Conference, March 19-22MannKind Corporation will showcase data from recent studies of inhaled insulin across five presentations at the 18thInternational Conference on Advanced Technologies and Treatments for Diabetes to be held March 19-22 in Amsterdam. In addition to the planned presentations, MannKind will host booth #40 in the exhibit hall (Hall I) throughout ATTD. Members of MannKind's Clinical Education Team will be available for scientific exchange in the medical section of the booth. INHALE-1 is a Phase 3, randomized controlled trial in children and teenagers aged 4-17 with type 1 or type 2 diabetes to evaluate the efficacy and safety of inhaled insulin in combination with basal insulin versus multiple daily injections of rapid acting insulin in combination with basal insulin. The 26-week, open-label clinical trial randomized 230 pediatric subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA) in combination with basal insulin. the primary endpoint was a non-inferior change in HbA1c levels after 26 weeks. The 17-week results shared that the study met its primary efficacy endpoint of a non-inferior Change in HbA1c between baseline and week 17 compared to the usual care group. The 30-week results from the study expanded upon the positive 17-week data and showed that more people living with T1D were able to reach target A1c levels when they remain on Afrezza (plus basal insulin) or switch to Afrezza from usual care. The signature technologies - dry- powder formulations and inhalation devices - offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that issues that develop in the review by the FDA may subject to unanticipated delays or prevent from obtaining the expanded indication as well as other risks detailed in MannKind's filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of its Annual Report on Form 10-K for the year ended December 31, 2025.
분석 기사 • Mar 01MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen NextMannKind Corporation ( NASDAQ:MNKD ) shareholders are probably feeling a little disappointed, since its shares fell...
공지 • Feb 27MannKind Corporation has filed a Follow-on Equity Offering in the amount of $200 million.MannKind Corporation has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Common Stock Security Type: Common Stock
공지 • Feb 20MannKind Corporation to Report Q4, 2024 Results on Feb 26, 2025MannKind Corporation announced that they will report Q4, 2024 results After-Market on Feb 26, 2025
공지 • Jan 07+ 1 more updateMannkind Corporation Announces Resignation of Lauren Sabella as Executive Vice President, Operations, Effective July 18, 2025MannKind Corporation announced Lauren Sabella notified company of her intention to retire from the Company, effective July 18, 2025, and the board of directors of the Company appointed Ms. Sabella as Executive Vice President, Operations, effective January 6, 2025. Ms. Sabella will continue to be a member of the Company’s executive leadership team until her retirement date, overseeing the same operations of the Company as in her prior role except that she will no longer oversee the operations of the Company’s Endocrine Business Unit.
Seeking Alpha • Dec 17MannKind Corporation: A Speculative Buy On IPF And Diabetes MarketsSummary MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, with significant market potential if successfully commercialized. The orphan lung pipeline includes MNKD-101 (Phase 3 for NTM lung disease) and MNKD-201 (Phase 1 for IPF), addressing high unmet needs. Despite high leverage, I believe MNKD's revenue growth prospects support a speculative "Buy" rating for investors seeking exposure to IPF and endocrine biotech niches. Read the full article on Seeking Alpha
공지 • Dec 16MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)MannKind Corporation announced six-month results from its Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). MannKind expects to submit a request for a supplemental new drug application (sNDA) meeting with the U.S. Food and Drug Administration (FDA) in 1H 2025 to discuss the data and filing timeline. The INHALE-1 study is a 26-week, open-label clinical trial that randomized 230 subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA) in combination with basal insulin. The primary endpoint was a non-inferior change in HbA1c levels after 26 weeks. A 26-week extension phase in which all remaining MDI patients switched to Afrezza is still ongoing. Results were as follows: mITT analysis excludes one outlier from the primary ITT endpoint who failed to adhere to the study protocol. An analysis of the full intent-to-treat population (ITT) found that the between-group difference in mean HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (0.435%), largely driven by the variability of a single patient who did not adhere to the study protocol. A modified ITT (mITT) analysis, which excluded this subject, did not exceed the predetermined threshold of 0.4% (0.370%), thereby establishing the non-inferiority of Afrezza to MDI, which was the primary endpoint of the study. Over 26 weeks of treatment, no difference in lung function parameters were seen between the treatment groups. The Afrezza-treated patients had a mean FEV1 of 2.901 liters (99.6% of predicted) at baseline and 2.934 liters (96.6% of predicted) at 26 weeks. MDI-treated patients had corresponding mean FEV1 values of 2.948 liters (102.3% of predicted) and 2.957 liters (98% of predicted), respectively. Additional safety findings, including for hypoglycemia, did not show any significant concerns or differences between the treatment groups.
공지 • Nov 05MannKind Corporation Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic DiseasesMannKind Corporation announced the successful completion of its first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The key highlights of the study included: Nintedanib DPI was shown to be safe and well tolerated in healthy volunteers with the tested doses and study duration; Participants did not experience typical adverse events seen with oral nintedanib; specifically, no GI or neurologic adverse events (AEs) were reported; Two types of AEs noted - cough and drop in FEV-1; These AEs were mild, transient, and fully recovered; These AEs were not dose-dependent and there was no pattern of recurrence or worsening with repeated dosing; No bronchospasm, wheezing, other symptoms, or change in vital signs were reported; No serious adverse events or study drug discontinuation. The completed Phase 1 was a single-site, randomized, placebo-controlled, single- (n=24) and multiple-ascending dose (n=16) study in healthy adult (older than 40 years old) participants. The primary objective of the study was to evaluate the safety and tolerability of nintedanib DPI. The secondary study objective was to evaluate the pharmacokinetics (PK) of MNKD-201. Additionally, the preclinical chronic toxicology study did not show any adverse findings and supports further development of nintedanib DPI.
공지 • Nov 01MannKind Corporation to Report Q3, 2024 Results on Nov 07, 2024MannKind Corporation announced that they will report Q3, 2024 results After-Market on Nov 07, 2024
Seeking Alpha • Oct 03MannKind Leverages Tyvaso DPI Strength In Pulmonary Market ExpansionSummary MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases. Financially, MannKind has strong liquidity but remains burdened by long-term debt obligations and modest net losses. I maintain a "buy" recommendation based on MannKind's solid revenue from Tyvaso DPI and its potential in expanding respiratory treatments. Read the full article on Seeking Alpha
공지 • Oct 01Mannkind Corporation Announces Top-Level 30-Week Results from Its Phase 4 Inhale-3 StudyMannKind Corporation announced top-level 30-week results from its Phase 4 INHALE-3 study, in which additional patients living with type 1 diabetes achieved target A1c levels during the extension phase. The completer analysis which included all people on inhaled insulin, evaluated two separate groups - one that utilized Afrezza®? (plus basal insulin) over 30 weeks, and a second group of patients who switched to Afrezza at week 17 from usual care, defined as multiple daily injections (MDI), an automated insulin delivery system, (AID) or a pump without automation. There was continued improvement in the Afrezza (plus degludec)-treated group, with additional subjects achieving A1c 1) to identify potential lung disease in all patients. Most common adverse reactions are hypoglycemia, cough, and throat pain or irritation.
공지 • Sep 19MannKind Corporation Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseMannKind Corporation announced that it has received clearance from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to initiate the Phase 3 study (ICoN-1) of Clofazimine Inhalation Suspension for the treatment of NTM lung disease. The global study is now cleared by health authorities to proceed in four countries (U.S., Japan, South Korea and Australia) with a fifth (Taiwan) expected in Fourth Quarter 2024. The ICoN-1 study was initiated in the United States in June 2024 and had its first patient randomized in September. In all, approximately 230 eligible participants will be enrolled and randomized at more than 100 sites across the U.S. and globally to ensure a minimum of 180 participants are evaluable for efficacy. Details of the ICoN-1 study and sites can be found at: ClinicalTrials.gov (NCT06418711).
분석 기사 • Sep 18MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift TooDespite an already strong run, MannKind Corporation ( NASDAQ:MNKD ) shares have been powering on, with a gain of 28% in...
새 내러티브 • Sep 12Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability Strong demand for Tyvaso DPI and advancements in pipeline drugs like clofazimine inhalation suspension highlight MannKind's successful commercial execution and promising revenue growth prospects.
공지 • Aug 14Mannkind Corporation Announces Board Changes, September 30, 2024MannKind Corporation announced that Kent Kresa has decided to retire from MannKind’s Board of Directors effective September 30, 2024. In addition, the Board of Directors has appointed Steven B. Binder to the Board, also effective September 30, 2024. Kresa, who has served on MannKind’s Board of Directors since June 2004, was Chairman from 2016 until December 2020. Upon his retirement from the MannKind Board, Mr. Kresa will continue to be associated with the company in the capacity of Chairman Emeritus. Binder previously served as MannKind’s Chief Financial Officer from July 2017 until April 2024 and currently serves as Executive Vice President, Special Projects. Mr. Binder will remain in that role until he joins the Board of Directors on September 30, 2024, after which he will no longer be an employee of the Company. With the addition of Binder, there will remain nine total members of the MannKind Board of Directors.
공지 • Jul 31MannKind Corporation to Report Q2, 2024 Results on Aug 07, 2024MannKind Corporation announced that they will report Q2, 2024 results Pre-Market on Aug 07, 2024
분석 기사 • Jul 17Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?Key Insights The projected fair value for MannKind is US$11.86 based on 2 Stage Free Cash Flow to Equity MannKind is...
공지 • Jun 22MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 StudyMannKind Corporation announced positive 17-week results from the INHALE-3 study, a Phase 4 U.S. clinical trial evaluating Afrezza® (plus basal insulin) vs. usual care (defined as multiple daily injections (MDI), an automated insulin delivery system, (AID) or a pump without automation) utilizing a higher initial conversion dose from mealtime injectable insulin to inhaled insulin. The study, which was presented by the INHALE-3 investigational team at the American Diabetes Association’s (ADA) 84th Scientific Sessions in Orlando, met its primary efficacy endpoint of a non-inferior change in HbA1c between baseline and week 17 compared to the usual care group. Key sub-analysis findings included: More subjects utilizing inhaled insulin achieved glycemic targets: 30% of inhaled insulin group reached <7% (HbA1c) at 17 weeks vs. 17% of the usual care group; 21% of inhaled insulin group vs. 0% of usual care group met A1c goal of <7% if baseline was >7%; 24% of the Afrezza group and 13% of the usual care group achieved TIR above 70% with no increased hypoglycemia in the inhaled insulin group. No difference in CGM-measured hypoglycemia between the groups; Study helps to establish a titrated basal-bolus ratio that is approximately 70/30 inhaled insulin to basal vs. 50/50 for usual care; While more people met the glycemic target of A1c (less than 7%) with Afrezza, some subjects worsened when switching from usual care to inhaled insulin, potentially due to missing doses of inhaled insulin during the day and/or underdosing going into bedtime; More than 50% of subjects at the end of the study expressed an interest in continuing to use Afrezza. The INHALE-3 study is a 17-week, randomized controlled trial with a 13-week extension conducted across 19 U.S. sites. The study, which enrolled 141 patients (123 randomized), assigned participants over 18 years of age with T1D who are using MDI, an automated insulin delivery system, or a pump without automation to either continue their standard of care or initiate an insulin regimen of a daily basal injection plus Afrezza for boluses (mealtime and corrections). Both arms utilized continuous glucose monitoring to assess glucose control. A1c levels were obtained at baseline, 17 and 30-weeks. The full 30-week results of INHALE-3 will be presented at future conferences.
Seeking Alpha • May 15MannKind Outperforms As Tyvaso DPI Captures Market ShareSummary MannKind's Q1 revenue rose 63% year-over-year; net income was $10.63 million, reversing a prior loss. Tyvaso DPI, utilizing MannKind’s technosphere technology, continues to capture significant PAH market interest. Despite high current assets, the Company's long-term liabilities exceed its assets, posing potential financial risks. Recommend buying MNKD for a barbell strategy portfolio, allocating a small portion to this high-alpha stock. Read the full article on Seeking Alpha
New Risk • May 09New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.5x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Negative equity (-US$230m). Minor Risk Shareholders have been diluted in the past year (3.0% increase in shares outstanding).
공지 • May 08MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseMannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation of Clofazimine Inhalation Suspension (MNKD-101) for the treatment of nontuberculous mycobacterial (NTM) lung disease. Fast track designation is intended to facilitate the development, and expedite the review, of medicines to treat serious conditions and fill an unmet medical need. ICoN-1 is a multi-national, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of Clofazimine Inhalation Suspension when added to guideline-based therapy in adults with refractory NTM lung disease caused by Mycobacterium Avium Complex (MAC), followed by an open-label extension. This single registrational study anticipates getting underway in June 2024 in the U.S., and internationally in the second half of 2024. The U.S. FDA previously designated Clofazimine Inhalation Suspension as both an orphan drug and a qualified infectious disease product (QIDP) for the treatment of pulmonary NTM infections. A drug that receives orphan drug exclusivity receives seven years of exclusivity, and one that also earns QIDP designation, may receive an additional five years of market exclusivity.
공지 • May 03MannKind Corporation to Report Q1, 2024 Results on May 08, 2024MannKind Corporation announced that they will report Q1, 2024 results on May 08, 2024
공지 • Apr 30+ 1 more updateMannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesMannKind Corporation announced that it will proceed with a first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The Phase 1 randomized, double-blind, placebo-controlled, single- (SAD) and multiple-ascending dose (MAD) study will evaluate the safety, tolerability, and pharmacokinetics (PK) of nintedanib inhalation powder (MNKD-201) in healthy volunteers. The Pulmonary Fibrosis Foundation indicates that there are over 250,000 Americans living with pulmonary fibrosis (PF) and 50,000 new cases are diagnosed each year. While it is unknown the number of people affected by IPF - the most common form of pulmonary fibrosis - the latest estimates indicate that 1 in 200 adults over the age of 70 are impacted i n the United States. The company committed to using formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. The company signature technologies - dry- powder formulations and inhalation devices - offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating nationwide, the company are on a mission to give people control of their health and the freedom to live life.
공지 • Apr 06MannKind Corporation, Annual General Meeting, May 15, 2024MannKind Corporation, Annual General Meeting, May 15, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect the nine nominees named herein as directors to serve for the upcoming year and until their successors are elected; to approve, on an advisory basis, the compensation of the named executive officers of company, as disclosed in company proxy statement for the Annual Meeting; and to discuss other matters.
공지 • Mar 27+ 1 more updateMannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024MannKind Corporation announced that Steven B. Binder will retire from his position as Chief Financial Officer, effective April 22, 2024. Mr. Binder plans to remain at the company through the end of the year as Executive Vice President, Special Projects. Christopher Prentiss has been appointed as Chief Financial Officer, effective April 22, 2024. Mr. Prentiss will be a member of the company’s executive leadership team and will report to Michael Castagna, Chief Executive Officer. Chris has over 20 years of experience serving in financial leadership positions within the biopharma industry in both private and public companies. Since September 2022, Mr. Prentiss has served as Chief Financial Officer of ADARx Pharmaceuticals Inc., where he helped to raise nearly $250 million in funding. Between April 2015 and November 2021, he held a series of finance positions of increasing responsibility at the commercial-stage biotech company Adamas Pharmaceuticals Inc., culminating in Chief Financial Officer. His responsibilities at Adamas included finance, accounting, investor relations, information technology and facilities. During his tenure, the company launched GOCOVRI® (in 2018) as well as acquired OSMOLEX® ER. At the time Adamas was acquired by Supernus Pharmaceuticals Inc. His earlier career also included senior financial roles at InterMune Inc., Dynavax Technologies Corporation and MannKind. Mr. Prentiss began his career in the assurance practice at KPMG LLP. A licensed CPA (inactive) in California, he earned his Bachelor of Science degree in Accounting from Loyola Marymount University and an MBA from Indiana University’s Kelley School of Business.
공지 • Mar 11MannKind Corporation Announces INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsMannKind Corporation announced initial meal challenge data from INHALE-3 that was presented by Dr. Irl B. Hirsch at the 17thInternational Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence on March 8th. INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care. The statistically significant findings included: Subjects utilizing inhaled insulin experienced significantly reduced post-meal hyperglycemia, compared with those who used subcutaneous rapid-acting analogues (RAA) delivered by MDI or pumps Area under the curve (AUC; 180 mg/dL) was reduced by 20%; Inhaled insulin subjects demonstrated significantly lower glucose excursions from baseline; Mean glucose excursions were reduced by 22%; In the inhaled insulin group, mean glucose levels peaked 15 minutes sooner than in the standard of care group despite inhaled insulin being given at start of the meal vs. RAA being administered 5-15 minutes prior to the meal. The 17-week endpoint results from INHALE-3 will be presented Saturday, June 22, during a symposium at the American Diabetes Association’s 84th Scientific Sessions in Orlando. INHALE-3 is a 17-week randomized controlled trial with a 13-week extension. The study, which enrolled 141 patients (123 randomized), assigned participants over 18 years of age with T1D who are using MDI, an automated insulin delivery system, or a pump without automation to either continue their standard of care or initiate an insulin regimen of a daily basal injection plus Afrezza for boluses (mealtime and corrections). Subjects utilizing inhaled insulin received a higher initial conversion dose than in the current label. Both arms utilized continuous glucose monitoring to assess glucose control. A1c levels were obtained at baseline, 17 and 30-weeks. For the meal challenge, the inhaled insulin group took an inhaled insulin dose immediately prior to a standardized meal (a 240 calorie nutritional shake) whereas those using usual care used RAA 5-15 minutes prior to the meal. Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis or in patients that smoke or have recently stopped smoking.
분석 기사 • Mar 03This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This YearCelebrations may be in order for MannKind Corporation ( NASDAQ:MNKD ) shareholders, with the analysts delivering a...
분석 기사 • Mar 02MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For ExcitementMannKind Corporation ( NASDAQ:MNKD ) shareholders would be excited to see that the share price has had a great month...
Reported Earnings • Feb 29Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.045 loss per share (improved from US$0.34 loss in FY 2022). Revenue: US$199.0m (up 99% from FY 2022). Net loss: US$11.9m (loss narrowed 86% from FY 2022). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 23%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
공지 • Feb 21MannKind Corporation to Report Q4, 2023 Results on Feb 27, 2024MannKind Corporation announced that they will report Q4, 2023 results on Feb 27, 2024
공지 • Feb 15MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®MannKind Corporation announced that it has fully enrolled 305 patients living with Type 1 or type 2 diabetes in its INHALE-1 study assessing efficacy and safety of inhaled insulin in the pediatric population. INHALE-1 is a 26-week open-label, randomized clinical trial with a 26-week extension. The primary endpoint is change in HbA1c level after 26 weeks. Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events. The multi-center study evaluated Afrezza in combination with basal insulin vs. multiple daily injections (MDI) of insulin in children and adolescents aged 4-17 who are living with type 1 or type 2 diabetes.
Seeking Alpha • Feb 15MannKind's Tyvaso DPI Royalty Deal Signals UndervaluationSummary MannKind sold a 10% stake in Tyvaso DPI for $150 million upfront, with an additional $50 million possible, indicating the potential value of the remaining 9% to be upwards of $1.8 billion. Liquidia's likely entry into the market with a competing formulation poses a slight concern but is unlikely to significantly impact MannKind's market share. MannKind's Q3 earnings showed a strong year-over-year surge, but concerns over equity dilution and a debt-heavy balance sheet remain. MannKind's strategic moves, financial strengthening via the Sagard deal, and a manageable competitive landscape advocate for a "Buy" rating. Read the full article on Seeking Alpha
분석 기사 • Jan 03MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is LackingMannKind Corporation's ( NASDAQ:MNKD ) price-to-sales (or "P/S") ratio of 6x might make it look like a strong buy right...
Recent Insider Transactions Derivative • Dec 17CEO & Director notifies of intention to sell stockMichael Castagna intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of December. If the sale is conducted around the recent share price of US$4.00, it would amount to US$400k. For the year to December 2016, Michael's total compensation was 16% salary and 84% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Michael's direct individual holding has increased from 2.15m shares to 2.35m. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
Reported Earnings • Nov 09Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: EPS: US$0.006 (up from US$0.056 loss in 3Q 2022). Revenue: US$51.3m (up 56% from 3Q 2022). Net income: US$1.72m (up US$16.2m from 3Q 2022). Profit margin: 3.4% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 9% per year.
공지 • Nov 07MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 DiabetesMannKind Corporation announced that it has fully enrolled patients in INHALE-3, a Phase 4 clinical trial evaluating inhaled insulin (combined with basal insulin) versus usual care in adults living with type 1 diabetes. INHALE-3 is a 17-week randomized controlled trial with a 13-week extension. The study will randomly assign participants over 18 years of age with T1D who are using Multiple Daily Injections (MDI), an automated insulin delivery (AID) system, or a pump without automation to either continue their usual care or adopt an insulin regimen of a daily basal injection plus Afrezza at mealtimes. Both arms will utilize continuous glucose monitoring to assess mealtime control and A1c levels.
공지 • Nov 01MannKind Corporation to Report Q3, 2023 Results on Nov 07, 2023MannKind Corporation announced that they will report Q3, 2023 results on Nov 07, 2023
Price Target Changed • Oct 10Price target increased by 9.8% to US$7.25Up from US$6.60, the current price target is an average from 6 analysts. New target price is 71% above last closing price of US$4.24. Stock is up 34% over the past year. The company is forecast to post a net loss per share of US$0.082 next year compared to a net loss per share of US$0.34 last year.
Reported Earnings • Aug 08Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.02 loss per share (improved from US$0.11 loss in 2Q 2022). Revenue: US$48.6m (up 157% from 2Q 2022). Net loss: US$5.27m (loss narrowed 82% from 2Q 2022). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 53%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 50% per year, which means it is well ahead of earnings.
공지 • Aug 01MannKind Corporation to Report Q2, 2023 Results on Aug 07, 2023MannKind Corporation announced that they will report Q2, 2023 results on Aug 07, 2023
공지 • Jun 23Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes (T1d)MannKind Corporation announced that it is launching the INHALE-3 study to address the most important unmet need in adults living with T1D. INHALE-3 is a 17-week randomized controlled trial with a 13-week extension. The study will randomly assign participants over 18 years of age with T1D who are using MDI, an automated insulin delivery (AID) system, or a pump without automation to either continue their usual care or adopt an insulin regimen of basal injections plus Afrezza. Both arms will utilize continuous glucose monitoring to assess mealtime control and A1c levels. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly, and symptoms may differ across patients and change over time in the same patient. Patients and caregivers should be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. Decline in Pulmonary Function: AFREZZA causes a decline in lung pulmonary function over time as measured by FEV1. In clinical trials excluding patients with chronic lung disease and lasting up to 2 years, AFREZZA-treated patients experienced a small (40 mL) but greater FEV1 decline than comparator-treated patients. Assess pulmonary function with pulmonary function at baseline, after the first 6 months of therapy and annually thereafter even in the absence of pulmonary symptoms. In patients who have a decline of =20% in FEV1 from baseline, consider discontinuing AFREZZA. Consider more frequent lung function assessment in patients with pulmonary symptoms, e.g., wheezing, bronchospasm, breathing difficult, or persistent or recurring cough. If symptoms persist, discontinue AFREZZA. In clinical trials, 2 cases of lung cancer were observed in patients exposed to AFREZZA while no cases were reported for the comparators. In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. Two additional cases of lung cancer (squamous cell and lung blastoma) were reported in non-smokers exposed to AFREZZA after the trial completion. These data are insufficient to determine whether AFREZZA has an effect on lung or respiratory tract tumors. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk of lung cancer, consider whether the benefits of AFREZZA use outweigh this potential risk.
Recent Insider Transactions Derivative • May 28CEO & Director notifies of intention to sell stockMichael Castagna intends to sell 150k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of May. If the sale is conducted around the recent share price of US$4.69, it would amount to US$703k. For the year to December 2016, Michael's total compensation was 16% salary and 84% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2022, Michael's direct individual holding has decreased from 2.05m shares to 1.98m. There has only been one transaction (US$18k sale) from insiders over the last 12 months.
공지 • May 25Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical OfficerMannKind Corporation announced Burkhard Blank, MD, has joined the company as Executive Vice President, Research & Development and Chief Medical Officer, effective today. Blank will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company’s executive leadership team. Dr. Blank brings to MannKind more than 25 years of broad managerial experience and global drug development across all clinical, medical, and regulatory disciplines in multiple diseases areas. He has deep knowledge in the inhaled therapeutics space and has been instrumental in eight NDA and MAA submissions for small molecules, biologics, and drug-device combinations. Dr. Blank recently served as CMO/Head of R&D at Pharnext SA after serving seven years in the same position at Acorda Therapeutics. While at Acorda, he oversaw the Phase 3 development in North America and in Europe for Inbrija® (levodopa inhalation powder) for Parkinson’s disease with subsequent one-cycle approvals by the FDA and the EMA. Earlier in his career, Dr. Blank spent 20 years between Boehringer Ingelheim Pharmaceuticals in Ridgefield, CT, and Boehringer Ingelheim GmbH in Germany, serving in progressive leadership roles. Under his guidance, four products received approval including Spiriva® (for COPD) for which he oversaw development and led the presentation at the FDA advisory committee meeting. He has proven success in large and small organizations and will be based in Danbury. He received his medical degree from Universitaet Marburg, Germany, and is board-certified in internal medicine.
분석 기사 • May 15Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share PriceWith a price-to-sales (or "P/S") ratio of 8.7x MannKind Corporation ( NASDAQ:MNKD ) may be sending bullish signals at...
Reported Earnings • May 10First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.037 loss per share (improved from US$0.10 loss in 1Q 2022). Revenue: US$40.6m (up 239% from 1Q 2022). Net loss: US$9.80m (loss narrowed 62% from 1Q 2022). Revenue exceeded analyst estimates by 8.6%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 55% per year, which means it is well ahead of earnings.
Major Estimate Revision • Mar 02Consensus EPS estimates fall by 17%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$167.0m to US$171.5m. Forecast EPS reduced from -US$0.12 to -US$0.14 per share. Biotechs industry in the US expected to see average net income decline 61% next year. Consensus price target up from US$6.17 to US$6.67. Share price fell 7.5% to US$4.83 over the past week.
Price Target Changed • Feb 27Price target increased by 8.1% to US$6.67Up from US$6.17, the current price target is an average from 6 analysts. New target price is 24% above last closing price of US$5.38. Stock is up 105% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$0.34 last year.
Reported Earnings • Feb 24Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$0.34 loss per share (further deteriorated from US$0.33 loss in FY 2021). Revenue: US$99.8m (up 32% from FY 2021). Net loss: US$87.4m (loss widened 8.0% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.7%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 62% per year, which means it is well ahead of earnings.
공지 • Feb 17MannKind Corporation to Report Q4, 2022 Results on Feb 23, 2023MannKind Corporation announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 23, 2023
분석 기사 • Jan 27MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share PriceKey Insights MannKind's estimated fair value is US$8.9 based on 2 Stage Free Cash Flow to Equity Current share price of...
공지 • Jan 24MannKind Corporation Announces its Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung DiseaseMannKind Corporation announced clofazimine inhalation suspension (MNKD 101) will advance to an adaptive Phase 2/3 study. Additionally, a paper has been published in the American Society for Microbiology journal Antimicrobial Agents and Chemotherapy examining the potential for treatment of nontuberculous mycobacterial (NTM) infection through direct delivery of inhaled clofazimine to the lungs, overcoming the systemic toxicity witnessed in oral treatments. Pulmonary NTM infection is recognized as a major global health concern due to its rising prevalence worldwide. It is a serious infection that is caused by bacteria common in the environment that can lead to a reduction in lung function, cough, fatigue, and quality of life. It is estimated that approximately 86,000-180,000 people in the U.S. alone are living with NTM lung disease, and it is on the rise growing 8% each year with women, the elderly, and those with underlying lung conditions at greatest risk. MNKD-101 has been designated by the FDA as both an orphan lung and a qualified infectious disease product (QIDP) for the treatment of pulmonary NTM infections. The 28-day preclinical toxicology study included toxicokinetic analyses on days 29, 56, and 84. The findings indicated: Significant residual drug in lung tissue, and long lung residence post-dosing at all three dose levels. Drug concentrations in the lung remained well above the average NTM minimum inhibitory concentration (MIC, for MAC and Mabsc) at all time points, with measurable clofazimine levels at 28- and 56-days post-dosing. Study MKC-CI-001 was a Phase I randomized, double-blind, placebo-controlled, single- (SAD) and multiple-ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of MNKD-101. The dosing study evaluated low, mid, and high doses of clofazimine administered using a jet nebulizer. The key safety findings of the study included: Clofazimine inhalation solution found to be generally well tolerated at daily doses of up to 90 mg. No lab abnormalities, QT prolongation, or serious adverse events were identified.
